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Summary
A decrease in functional insulin-producing pancreatic β-cells contributes to the es-
tablishment of not only type 1 but also of type 2 diabetes. Fas (CD95) is a cell
surface receptor which plays a central role in the regulation of death in many cell
types including β-cells and may be implicated in the development of type 1 and 2
diabetes. Glucose-induced β-cell apoptosis in human islets involves IL-1β mediated
up-regulation of Fas and subsequent interaction with the constitutively expressed
Fas ligand (FasL) on neighboring β-cells. Fas/FasL interaction leads to cleavage
of procaspase-8, the most upstream caspase in the Fas apoptotic pathway. However,
elevated glucose concentrations have a dual effect on β-cell turnover inducing prolif-
eration in the short-term and apoptosis in the long-term . This dual effect of glucose
may be explained by the pivotal role of FLICE-inhibitory protein (FLIP) on Fas sig-
naling. Here we show that the Fas pathway also regulates β-cell secretory function.
We observed impaired glucose tolerance in Fas deficient mice due to a delayed and
decreased insulin secretory pattern. Expression of PDX-1, a β-cell specific tran-
scription factor regulating insulin production and mitochondrial metabolism, was
decreased in Fas deficient β-cells. As a consequence, insulin and ATP produc-
tion were severely reduced and partly compensated for by a dramatic increase in
β-cell mass. Up-regulation of FLIP enhanced NF-κB activity via NF-κB-inducing
kinase and RelB. This led to increased PDX-1 and insulin production independent
of changes in cell turnover. Several observations point to a role for the Fas path-
way in the regulation of cell-cycle independent events including T cell activation,
renal tubular epithelial integrin function, and protection against neurodegeneration.
However, a direct interaction between the Fas pathway and PDX-1 has not been in-
vestigated.
Looking upstream of Fas, at IL-1β, we show that IL-1β at low concentrations may
participate in the mitogenic actions of glucose through the Fas-FLIP pathway. Thus,
exposure of human islets to low IL-1β concentrations (0.01–0.02 ng/ml) stimulated
proliferation and decreased apoptosis whereas 2–5 ng/ml of IL-1β had the reverse ef-
fect. A similarly bimodal induction of FLIP, PDX-1 and Pax4 mRNA expression as
well as glucose-stimulated insulin secretion was observed. In contrast, Fas induction
by IL-1β was monophasic. Low IL-1β also induced the IL-1 receptor antagonist (IL-
1Ra), suppression of which by RNA interference abrogated the beneficial effects of
low IL-1β. The Fas antagonistic antibody ZB4 and siRNA to FLIP prevented low IL-
1β-stimulated β-cell proliferation. Consistent with our in vitro results, IL-1β knock-
out mice displayed glucose intolerance, similar to that seen in the Fas-deficient mice,
along with a decrease in islet Fas, FLIP, Pax4 and PDX-1 transcripts. These find-
ings indicate that low IL-1β levels positively influence β-cell function and turnover
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through the Fas-FLIP-pathway, and that IL-1Ra production prevents harmful effects
of high IL-1β concentrations.
Type 2 diabetes is characterized by a deficit in β-cell mass and its incidence in-
creases with age. In cultivated human islets, age correlated positively with the sen-
sitivity to glucose-induced β-cell apoptosis and negatively to baseline proliferation.
In rat islets, constitutive expression of Fas-ligand (FasL) and glucose-induced Fas
receptor expression were observed only in older islets. Moreover, PDX-1 expression
decreased with age in pancreatic tissue sections of rats and humans. Furthermore,
older rat islets were more sensitive to the high glucose mediated decrease in PDX-
1 expression than younger islets. Although type-2 diabetes has been accepted and
known to be a ’maturity’ onset disease, this was thought to be due to genetic pre-
disposition or lifestyle. Our research has shed light on the issue by implicating the
disappearance of PDX-1 and FLIP which could now be used as possible targets for
treatment of the disease.
We have also implicated the Fas receptor in the development of insulin resistance.
Exposing Fas-deficient mice to a high fat diet, surprisingly resulted in no beta-cell
impairment, no insulin resistance compared to wildtype mice on the high fat diet,
improved PDX-1 and insulin mRNA as well as improved glucose stimulated insulin
release, compared to Fas-deficient mice on normal chow.
The Fas/FLIP pathway, therefore, may play an important role in type 2 diabetes.
To further elucidate this role, we generatedβ-cell-specific-FLIP overexpressing mice.
These mice had increased β-cell mass, increased insulin mRNA, and improved fast-
ing glucose as the mice aged. Finally, the islets displayed immune cell infiltration,
probably due to the induction of IL-8, a chemokine implicated in the attraction of
immune cells but also in increased angiogenesis and tumour growth.
Inflammation has always been linked with type 1 diabetes, yet our results show a
clear role of cytokines in the impairment of β-cell function as well as in destruction
of β-cell mass in a type 2 diabetic milieu. The novelty of this idea has opened up
the field of type 2 diabetes to new treatment strategies. A possible treatment would
be the use of Interleukin-1 Receptor Antagonist (IL1-Ra), which blocks the action
of IL-1β; upregulating FLIP expression in the β-cells to increase β-cell mass and
function; or partially blocking the Fas receptor in the β-cell or peripheral tissue thus
preventing insulin resistance but the increased beta-oxidation due to the high fat diet
would increase β-cell ATP levels and thus increase insulin secretion.
Zusammenfassung
Die pankreatische β-Zellmasse und Funktion wird bei erho¨htem Insulinbedarf wie
bei der Adipositas heraufreguliert. Das Versagen dieser Anpassung resultiert in der
Manifestation des Diabetes Mellitus. Die molekularen Mechanismen, welche die-
sen adaptiven Prozess steuern, sind noch unklar. Dabei ist Fas, ein
”
death Recep-
tor“, von Bedeutung. Er kontrolliert die β-Zellapoptose oder Proliferation, je nach
Aktivita¨t des caspase-8 Inhibitor FLIP. Wir zeigen hier, dass die Fas Signalkaska-
de auch die sekretorische β-Zellfunktion reguliert. So beobachteten wir eine be-
eintrchtige Glukosetoleranz in den Fas-defizienten Ma¨usen. Dies zeigte sich an-
hand eines verzo¨gerten und verminderten Insulinsekretionsmusters. Von Bedeutung
ist die in Fas-defizienten β-Zellen verminderte Expression von PDX-1, ein β-Zell-
spezifischer Transkriptionsfaktor, welcher die Insulinproduktion und mitochondriale
Funktion steuert. Als Konsequenz war die Insulin und ATP-Produktion schwerst-
gradig reduziert und daher teilweise durch eine dramatische erho¨hte β-Zellmasse
kompensiert. Aufregulation von FLIP versta¨rkte die NFκB Aktivita¨t via NFκB-indu-
zierende Kinase und RelB. Dies fu¨hrte zu einer Erho¨hung der PDX-1 und Insulin-
produktion unabha¨ngig vom Zellumsatz.
Hohe Glukosekonzentrationen haben einen dualen Effekt auf den β-Zellumsatz.
Kurzzeitig wird die Proliferation induziert, la¨ngerfristig jedoch die Apoptose aufre-
guliert. Die β-Zellen produzieren durch die Hyperglyka¨mie IL-1β, welches das Fas
reguliert. Hier wird gezeigt, dass IL-1β in niedrigen Konzentrationen an der mitoge-
nen Wirkung der Glukose via Fas-FLIP Kaskade beteiligt sein ko¨nnte. Daher, nach
Exposition humaner Inseln mit niedriger IL-1β Konzentrationen (0.01–0.02 ng/ml),
wurde eine Stimulierung der Proliferation und einen Minderung der Apoptose re-
gistriert. Im Gegensatz dazu hatten ho¨here Konzentrationen von IL-1β (2–5 ng/ml)
den gegenteiligen Effekt. Derselbe bimodale Effekt wurde auch in der Induktion der
FLIP, PDX-1 und Pax4 mRNA Expression wie auch bei der Glukose-stimulierte In-
sulinsekretion verzeichnet. Dagegen war die Induktion des IL-1β monophasisch. Zu-
dem induzierten niedrige IL-1β Konzentrationen den IL-1 Rezeptor Antagonist (IL-
1Ra). Wurde der IL-1Ra durch RNA-Interferenz unterdru¨ckt, hoben sich die gu¨nsti-
gen Effekte von niedriger IL-1β Konzentration wieder auf. Der Fas-antagonistische
Antiko¨rper ZB4 und die FLIP siRNA verhinderten die durch niedrige IL-1β Kon-
zentrationen stimulierte β-Zellproliferation. In ¨Ubereinstimmung mit unseren
”
in
vitro“-Experimenten, zeigten die
”
IL-1β-knockout“-Ma¨use eine Glukoseintoleranz
sowie Erniedrigung in den Fas, FLIP, Pax4 und PDX-1 Transkripten der Inseln. Die-
se Erkenntnisse weisen darauf hin, dass niedrige IL-1β Levels die β-Zellfunktion
und Turnover mittels Fas-FLIP Kaskade positiv beeinflussen. Zudem zeigt dies auch,
dass die IL-1Ra Produktion den scha¨dlichen Effekt von hoher IL-1βKonzentrationen
v
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verhindert.
Der Diabetes Typ 2 ist charakterisiert durch ein Defizit in β-Zellmasse und sein
vermehrtes Auftreten in fortschreitendem Alter. Wir analysierten den β-Zellumsatz
der Inseln von Ratten verschiedenen Alters (2–3 Monate vs. 7–8 Monate) und von
Organspendern mit einer Altersspanne von 17 bis 74 Jahre. Die kultivierten Inseln
der 2–3 Monate alten Ratten zeigten bei einer Erho¨hung der Glukosekonzentrati-
on von 5.5 auf 11.1 mM eine verminderte β-Zellapoptose, welche jedoch bei Stei-
gerung der Glukosekonzentration auf 33.3 mM zunimmt. Parallel dazu konnte so-
wohl bei 11.1 als auch bei 33.3 mM Glukose eine erho¨hte Proliferation, verglichen
mit 5.5 mM Glukose, verzeichnet werden. Im Gegensatz dazu beobachteten wir bei
den 7–8 Monate alten Ratten und erwachsenen Menschen eine lineare Zunahme des
β-Zelltodes und Abnahme der Proliferation bei steigender Glukosekonzentrationen
(5.5 bis 33.3 mM). Zusa¨tzlich korrelierte bei kultivierten humanen Inseln das Alter
positiv mit der Empfa¨nglichkeit fu¨r glukoseinduzierte β-Zellapoptose und negativ
mit der Basisproliferation. Die Inseln der 7–8 Monate alten Ratten zeigten im Ge-
gensatz zu den der 2–3 Monate alten Ratten eine konstitutive Expression von Fas-
Ligand (FasL) und des glukoseinduzierten Fas-Rezeptors. Daru¨ber hinaus wurde in
den pankreatischen Gewebsschnitten von Mensch und Ratte eine mit zunehmendem
Alter verminderte PDX-1 Expression nachgewiesen. Zusa¨tzlich sind die a¨lteren Rat-
teninseln anfa¨lliger auf die, durch eine hohe Glukosekonzentration vermittelte, Er-
niedrigung von PDX-1. Somit ko¨nnte man die Unterschiede in der Glukosesensi-
tivita¨t zwischen den humanen Inseln und den Inseln der 2–3 Monate alten Ratten
vielmehr auf altersabha¨ngige Vera¨nderungen als auf den genetischen Hintergrund
zuru¨ckfu¨hren. Diese Daten liefern eine mo¨gliche Erkla¨rung fu¨r das vermehrte Auf-
treten des Diabetes Typs 2 im fortschreitendem Alter. Auerdem weisen sie darauf
hin, dass Inseln a¨lterer Ratten ein passenderes Model fu¨r die Erforschung der gluko-
seinduzierte β-Zellapoptose sind.
Wir etablierten ein
”
high-fat“ induziertes diabetisches Tiermodell. Diese Ma¨use
entwickelten nach 4-wo¨chiger
”
high-fat“ Dia¨t eine beeintra¨chtigte Glukosetoleranz
und Insulinresistenz. ¨Uberraschende Resultate ergaben sich durch die Exposition
der Fas-defizienten Ma¨use mit dieser Dia¨t. Gegenu¨ber den Fas-defizienten Ma¨usen
mit normaler
”
chow“ Dia¨t verbesserte sich die Glukosetoleranz und normalisierte
sich die erste und zweite Phase der Insulinsekretion. Zudem entstand bei den Fas-
defizienten Ma¨usen im Vergleich zu den Wiltypen-Ma¨usen mit
”
high-fat“ Dia¨t auch
keine Insulinresistenz. Die Analyse der Inseln von den unter der
”
high-fat“ Dia¨t
gehaltenen Fas-defizienten Ma¨usen ergab eine Erho¨hung in den Insulin und PDX-
1 mRNA Levels sowie eine Verbesserung der glukosestimulierten Insulinsekretion.
Um die
”
in vivo“-Situation nachzuahmen, fu¨hrten wir
”
in vitro“-Experimente durch,
bei denen Fas-defiziente Inseln einer Mixtur von Palmitat und Oleat ausgesetzt wur-
den. Die, mit Fettsa¨uren behandelten, Fas-defizienten Inseln zeigten ebenfalls eine
Verbesserung der glukosestimulierten Insulinsekretion gegenu¨ber den unbehandel-
ten Fas-defizienten Inseln, wobei die Wildtypen-Inseln nach derselben Fettsa¨ure-
Exposition eine verminderte Funktion aufwiesen. Ebenso zeigte sich, im Gegensatz
zu den Wildtypen-Inseln, keine Beeintra¨chtigung der glukosestimulierten Insulinse-
kretion nach Exposition der Fas-defizienten Inseln mit chronischer Hyperglyka¨mie.
Es gibt drei mo¨gliche Theorien, welche die verbesserte Insulinsekretion der Fas-
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defizienten Maus nach Behandlung mit
”
high-fat“ Dia¨t oder der Fas-defizienten In-
seln nach Fettsa¨ure-Exposition erkla¨ren ko¨nnten: 1) Schutz der Fas-defizienten In-
seln gegenu¨ber der Fettsa¨ureexposition. 2) Wiederaufnahme der Insulinsekretion via
ATP-Produktion durchβ-Oxidation der Fettsa¨ure. 3) Unfa¨higkeit der Fas-defizienten
Ma¨use eine Insulinresistenz zu entwickeln.
Die Fas-FLIP Kaskade scheint daher eine wichtige Rolle im Diabetes Typ 2 zu
spielen. Um diese Rolle weiter zu erforschen, generierten wir Ma¨use, welche β-Zell-
spezifisch FLIP u¨berexprimieren. Diese Ma¨use hatten im Alter eine gesteigerte β-
Zellmasse, erho¨hte Insulin mRNA und verbesserte Nu¨chternglukose. Ebenso zeigten
die Inseln ein Infiltrat von Immunzellen, wahrscheinlich aufgrund der Induktion von
IL-8, ein Chemokin, welches chemoattraktiv auf neutrophile Granulozyten wirkt und
in Zusammenhang mit der Angiogenese und Tumorwachstum gebracht wird.
Somit scheint die Fas-FLIP Kaskade eine wichtige Rolle in der Insulinsynthese
und Sekretion zu spielen.
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1 Introduction
1.1 Pancreas
The pancreas consists of exocrine and endocrine cells which produce pancreatic di-
gestive enzymes and endocrine hormones, respectively. The bulk of the pancreas
consists of exocrine cells, called acini, and embedded in the exocrine tissue are the
endocrine cells, called the Islets of Langerhans, which form approximately 1% of
the total mass of the pancreas. The pancreatic digestive enzymes, secreted by the
exocrine pancreas, are secreted into the intestine where they digest proteins, fats and
carbohydrates.
Although the Islets of Langerhans form such a small part of the pancreas, the
function of the cells are vastly important to the homeostasis of the body. The Islets
of Langerhans consist of the following cell types:
• β-cells secrete insulin (60–80%)
• α-cells secrete glucagon (10–20%)
• δ-cells secrete somatostatin ( 5%)
• PP-cells contain pancreatic polypeptide (< 1%)
The cytoarchitecture of the rodent islet is the α cells found on the periphery, encir-
cling the β-cells and the interspersed δ and PP cells (Figure 1.1). The hormones
secreted by these cells have an important role in regulating blood glucose in the fed
and fasted state. Insulin and glucagon have opposite effects on blood glucose levels.
When blood glucose levels are high (e. g. after a meal), the β-cell produces more
insulin which acts on different cells, including muscle, liver and fat cells, thus in-
creasing the uptake of glucose into the cells and returning circulating blood glucose
to normal. The α cells secrete glucagon when blood glucose levels are low e. g.
after exercise or in-between meals. Glucagon mainly acts on the liver causing glu-
coneogenesis and the release of stored glucose into the bloodstream. Somatostatin is
secreted in response to high levels of the other pancreatic endocrine hormones and
thus regulates the production of these hormones. Pancreatic polypeptide (PP) is re-
leased in response to a meal ingestion and has been shown to affect the secretion of
pancreatic enzymes, gastric emptying and gallbladder motility and appears to be a
modulator of peripheral insulin action.
There are many diseases of the pancreas, but in this thesis we are mainly focussing
on Diabetes.
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Figure 1.1: The structure of a pancreas.
1.2 Diabetes
With lifestyles becoming more sedentary, the incidence of obesity has increased and
so has the incidence of type 2 diabetes, so much so that the terms obesity and type 2
diabetes are becoming synonymous. Many obese individuals, however, only develop
insulin resistance, as the β-cell is able to compensate by increasing in functional β-
cell mass. In those individuals where diabetes develops, insufficient compensation
occurs which leads to a relative insulin deficiency, glucose intolerance and therefore
increased circulating glucose concentrations or hyperglycaemia. Once hypergly-
caemia is present, the loss of β-cell mass accelerates accompanied by impairment of
the β-cell secretory function, both factors of which are needed for the manifestation
of type 2 diabetes. The preservation of a functional β-cell mass and the elucidation
of the decline in β-cell function, therefore, have become the focal point of research
in diabetes.
1.2.1 Glucose and the IL-1β-Fas-FLIP pathway
Under normal conditions, insulin (Figure 1.2) secretion is tightly regulated by the
metabolic requirements of the tissues and the circulating glucose concentrations.
The breakdown of glucose results in an increase in adenosine triphosphate (ATP),
which increases the ATP/ADP ratio (Figure 1.3). The change in ratio closes the
ATP-dependent potassium channel (K+ATP channel) in the cell membrane, which
in turn depolarizes the cell membrane. The calcium (Ca2+) channels open, resulting
in an influx of Ca2+ into the cytoplasm and insulin exocytosis [2]. Insulin secretion
is phasic, with a first phase of secretion which has a duration of less than 10 min,
followed by a longer second phase secretion. This is probably due to the existence of
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Figure 1.2: Left: Carbon is denoted in green, Hydrogen in white, Oxygen in red and
Nitrogen in blue. Right: An insulin monomer with the A chain coloured in blue,and the B
chain in cyan. Yellow denotes the disulphide bonds and magenta the zinc ions. Adapted
from Chang et al. [1].
two pools of insulin granules, with the first phase secretion developing from a read-
ily available pool primed for secretion [2]. Once released, insulin binds to insulin
receptors which are expressed ubiquitously, leading to modifications of a number of
biological processes, such as cell survival, glucose transport and lipid metabolism.
When insulin binds to its receptor, it activates tyrosine kinase, autophosphorylat-
ing tyrosine residues on the receptor β-subunit which in turn phosphorylates the in-
sulin receptor substrate proteins (IRS) [3]. The biological process activated depends
on which of the IRS proteins are phosphorylated. IRS-1 is mainly involved in cell
growth and insulin action in the muscle and adipose tissue. IRS-2 is important for
β-cell survival and growth, amongst other things[4]. These functions depend on the
recruitment and activation of any of the various downstream signalling molecules,
such as phosphatidylinositol 3-kinase (PI 3-kinase), growth factor receptor binding
protein 2 (Grb-2) and SH2-containing protein-tyrosine phosphatase-2 (SHP-2)
In cultured human islets, glucose has been shown to induce β-cell proliferation
in the short-term but chronically, induced β-cell apoptosis. This duality in function
centres around a cell surface receptor called Fas (CD95). Fas belongs to the TNF re-
ceptor superfamily and is a transmembrane protein with three extracellular cysteine-
rich domains [5]. There are 4 steps to the initial signalling events of the Fas receptor:
trimerization, recruitment, surface clusters and internalization. Binding of Fas ligand
(FasL) to Fas, causes trimerization of the Fas receptor and recruitment of the adap-
tor molecule, Fas-associated death domain protein (FADD) and procaspase-8 into
the death-inducing signaling complex (DISC) (Figure 1.4). Caspases are a family
of aspartate-specific cysteine proteases that are synthesised as proenzymes, activated
by proteolytic activity and are required for apoptosis [6, 7]. Procaspase-8 binds to
FADD through its N-terminal death effector domain (DED) [8]. Procaspase-8 cleav-
age occurs via 2 steps: initial cleavage generates a p43 and p12 fragment further
processed to a p10 fragment. Subsequent cleavage of the receptor-bound p43 results
in formation of the prodomain p26 and the release of the active fragment p18 [8].
Cleavage occurs via a trans-and autocatalytic cleavage due to the close proximity of
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Figure 1.3: Schematic of glucose-induced insulin secretion.
the procaspase-8 molecules to each other [6] Prolonged activation of Fas results in all
procaspase-8 being activated to caspase-8. Caspase-8 then activates other caspases
further downstream, setting a cascade in motion with the end result being apoptosis.
Since exposure of β-cells to glucose resulted in an increase in proliferation in
the short-term and since not all activation of the Fas receptor resulted in apoptosis,
it became clear that an inhibitor or anti-apoptotic molecule must exist in the Fas
pathway. At first, this molecule was known by many names, FLAME-1, CASPER,
FLIP, Usurpin, CLARP, I-FLICE, MRIT, as it was discovered independently in many
groups [10–13]. FLIP is an unstable protein which is rapidly degraded via the
ubiquitin-proteosome pathway. FLIP is predominantly expressed in the heart and
lymphoid tissue but is also expressed in the kidneys and pancreas [10]. NFκB,
protein synthesis inhibitors, calcium/calmodulin-dependent protein kinase II, bile
acids, heat stress, transforming growth factor beta, oxidised LDL, and p53 are pos-
sible regulators of FLIP expression [6, 14–21]. Two splice variants of FLIP exist,
called FLIP-Short( FLIPS) and FLIP-Long (FLIPL). FLIP has a similar structure to
caspase-8 though FLIPS only contains 2 death effector domains and FLIPL contains
2 death effector domains and an additional inactive caspase-like domain. Both FLIPS
and FLIPL are recruited to FADD and block activation of procaspase-8 to caspase-8,
thus inhibiting apoptosis. FLIPS completely blocks any processing of procaspase-8
as it contains no caspase-like domain, whereas FLIPL allows the first cleavage step
of procaspase-8 to p10, but further processing is inhibited [7, 22].
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Figure 1.4: The Fas pathway, which depending on the presence of FLIP can be apoptotic
or proliferative. Adapted from Budd [9].
When insulin signalling is disrupted or insulin resistance occurs, circulating glu-
cose concentrations increase resulting in chronic hyperglycaemia. Chronic hypergly-
caemia has severe adverse effects on β-cell function causing glucose desensitization,
β-cell exhaustion and finally the irreversible reduction of insulin secretion as well
as insulin stores. This is termed glucotoxicity. Chronic hyperglycaemia induces
Fas expression via the cytokine IL-1β. Fas expression induced by cytokines in the
β-cell requires the activation of NFκB. Nuclear Factor kappa B (NFκB) does not
refer to one molecule but rather to a group of proteins (RelA, RelB, c-Rel, p105/p50
and p100/p52) which share a conserved N-terminal region called a Rel homology
(RH) domain [23]. This RH domain contains the DNA-binding and dimerization do-
mains and the nuclear localization signal (NLS) which enables the regulation of the
nuclear-cytoplasmic shuttling of NFκB [24]. There are two main NFκB signalling
pathways:
• classical or canonical pathway,
• alternative or non-canonical pathway.
Classical / Canonical pathway
NFκB is activated by various extracellular stimuli such as Tumor necrosis factor al-
pha (TNFα), interleukin 1-beta (IL1-β), and Fas (Figure 1.5). When the canonical
pathway is activated, the IkappaB (IκB) kinase (IKK) complex which consists of two
kinase subunits, IKKα and IKKβ and a structural subunit IKKγ or NEMO (NFκB
essential modulator), phosphorylates IκBα [23–25]. IκB is attached to a heterodimer
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Figure 1.5: NFκB has two main pathways, canonical and alternative. Adapted from Beinke
and Ley [25].
consisting of p50 and RelA (also called p65). IκB’s, the NFκB inhibitors, sterically
block the function of the nuclear localization signal of the NFκB dimers thus pre-
venting nuclear translocation [23]. Immediately after phosphorylation, the IκBα is
ubiquitinated and soon thereafter degraded by the 26S proteosome. The degradation
of IκBα frees the p50/RelA heterodimer, which translocates into the nucleus, binds
to the promoter regions of NFκB-responsive genes such as IL1-β and interleukin-6
(IL6), and modulates their expression [25].
Alternative / non-canonical pathway
Activation of the alternative pathway results in phosphorylation of the IKKα homod-
imer and thus activation of its kinase activity by NFκB-inducing kinase (NIK) (Fig-
ure 1.5). A mutation in NIK, as occurs in the alymphoplasia (aly/aly) mice, inhibits
further processing of this pathway. The phosphorylated IKKα homodimer phos-
phorylates p100 which is bound to RelB. p100 also functions as an IκB as it has
an ankyrin repeat region in the C-terminal. After phosphorylation, p100 is slowly
processed by proteolysis to form p52, which together with RelB translocates to the
nucleus.
The NFκB pathway has mainly been linked with the regulation of immune and
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inflammatory responses, but more recent evidence has linked it with cell prolifera-
tion, apoptosis and insulin secretion [5, 19]. Although FLIP is regulated by NFκB,
evidence indicates that NFκB is in-turn regulated by FLIP [19, 26–29].
1.2.2 Age and Diabetes susceptibility
The fact that type 2 diabetes predominantly occurs in older individuals is an ac-
cepted fact, especially as this disease is known as ’adult onset diabetes’. Although
human islets constitutively express FasL, human islets from older organ donors are
more susceptible to glucose-induced apoptosis. It is a well known fact that glu-
cose is the principle regulator of insulin biosynthesis, both at the transcriptional and
post-transcriptional levels via the pancreatic duodenal homeobox (PDX-1) [30–33].
PDX-1 is a transcription factor expressed in β-cells, some δ cells, in dispersed en-
docrine cells of the duodenum and in the developing brain [32]. As seen in ho-
mozygous PDX-1 knockout mice, PDX-1 is important for the development of the
pancreas [34]. In the adult mouse, however, PDX-1 mainly regulates insulin gene
expression, but also plays a role in glucose transporter 2 (GLUT-2), glucokinase, and
islet amyloid polypeptide regulation [35]. Prolonged exposure of human, mouse, or
rat islets to high glucose results in a decrease in PDX-1 mRNA as well as a decrease
in insulin mRNA, resulting in impaired function of the β-cell [33, 36–42]. Marshak
et al. [37] found that chronic exposure to high glucose in human islets lowers PDX-1
binding activity. The difference in function of PDX-1 from pancreatic development
to insulin gene expression in adulthood, made us question its role in the development
of diabetes with age.
1.2.3 Free fatty acids and Diabetes
Free fatty acids (FFA) are elevated in obese individuals and have been implicated in
the loss of insulin sensitivity and thus the onset of insulin resistance [43]. Lowering
free fatty acid concentrations in diabetic individuals, resulted in normalized insulin
sensitivity [44]. Free fatty acids don’t only affect the peripheral tissues (skeletal
muscle and liver), but also directly affect the β-cells. FFAs acutely stimulate insulin
secretion but chronic exposure of islets to FFAs results in desensitisation and sup-
pression of insulin secretion [45]. In the Zucker Diabetic Fatty (ZDF) rat it has been
found that high circulating FFAs and triglyceride levels induce triglyceride accumu-
lation in islets [46]. This increase in triglyceride levels causes β-cell apoptosis via
the ceramide pathway. Not all obese individuals or type 2 diabetes susceptible indi-
viduals exhibit dyslipidemia. It is therefore possible that though lipotoxicity plays
an important role in β-cell destruction, the situation is probably worsened in the
presence of high glucose concentrations, thus leading to the phenomenon, glucol-
ipotoxicity.
Since NFκB which is needed for insulin secretion is found downstream of both IL-
1β and Fas, we hypothesised that both IL-1β and Fas are needed for β-cell function
and insulin secretion.
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Abstract
Pancreatic β-cell mass and function increase in conditions of enhanced insulin
demand such as obesity. Failure to adapt leads to diabetes. The molecular
mechanisms controlling this adaptive process are unclear. Fas is a death re-
ceptor involved in β-cell apoptosis or proliferation, depending on the activity
of the caspase-8 inhibitor FLIP. Here we show that the Fas pathway also reg-
ulates β-cell secretory function. We observed impaired glucose tolerance in
Fas deficient mice due to a delayed and decreased insulin secretory pattern.
Expression of PDX-1, a β-cell specific transcription factor regulating insulin
production and mitochondrial metabolism, was decreased in Fas deficient β-
cells. As a consequence, insulin and ATP production were severely reduced and
partly compensated for by a dramatic increase in β-cell mass. Up-regulation of
FLIP enhanced NF-κB activity via NF-kappaB-inducing kinase and RelB. This
led to increased PDX-1 and insulin production independent of changes in cell
turnover. The results support a role for the Fas-pathway in regulating insulin
production and release.
2.1 Introduction
A decrease in functional insulin-producing pancreatic β-cells contributes to the es-
tablishment of not only type 1 but also of type 2 diabetes [1–3]. Fas (CD95) is a
cell surface receptor which plays a central role in the regulation of death in many
cell types including β-cells and may be implicated in the development of type 1 and
2 diabetes [4–6]. Glucose-induced β-cell apoptosis in human islets involves IL-1β
mediated up-regulation of Fas and subsequent interaction with the constitutively ex-
pressed Fas ligand (FasL) on neighboring β-cells [7–10]. Fas/FasL interaction leads
to cleavage of procaspase-8, the most upstream caspase in the Fas apoptotic path-
way. However, elevated glucose concentrations have a dual effect on β-cell turnover
inducing proliferation in the short-term and apoptosis in the long-term [7, 11, 12].
This dual effect of glucose may be explained by the pivotal role of FLICE-inhibitory
protein (FLIP) on Fas signaling. FLIP structurally resembles caspase-8 but lacks its
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proteolytic activity [13]. FLIP is expressed in human pancreatic β-cells, and is de-
creased in the pancreatic tissue of type 2 diabetic patients as well as in cultured islets
following prolonged exposure to elevated glucose concentrations [14]. Upregulation
of FLIP switches Fas-mediated glucose signaling in β-cells from being apoptotic to
favoring cell replication [14].
The transcription factor nuclear factor-κB (NF-κB) is an essential component of cy-
tokine signaling. Interestingly, in β-cells, NF-κB activation can also be triggered
by glucose [8, 15]. Increasing evidence points to non-inflammatory effects of NF-
κB, including regulation of insulin secretion [16]. NF-κB is activated by signal-
ing through many receptors, which can be grouped into the classical pathway and
the non-classical pathway of NF-κB activation [17]. In the classical pathway, up-
stream signals induce phosphorylation of IκBα bound to cytosolic NF-κB. Phos-
phorylation is carried out by the IκB kinase (IKK) complex, which is composed of
IKK-γ and two catalytic subunits, IKK-α and IKK-β. Phosphorylation tags IκBα
for ubiquitylation and, ultimately, for proteasomal degradation, liberating NF-κB
(p50 and RelA or p65) for translocation to the nucleus and subsequent activation
of target genes. The non-classical pathway is controlled through NF-κB-inducing
kinase (NIK) which phosphorylates IKK-α; this regulation occurs independently of
the classical IKK complex and leads to processing of p100, generating p52-RelB
heterodimers, which migrate to the nucleus.
The β-cell specific transcription factor PDX-1 predominantly regulates β-cell dif-
ferentiation and secretory function. In particular, PDX-1 controls several events in
glucose stimulated insulin secretion including mitochondrial metabolism [18–21].
Several observations point to a role for the Fas pathway in the regulation of cell-
cycle independent events including T cell activation [22], renal tubular epithelial
integrin function [23], and protection against neurodegeneration [24]. However, a
direct interaction between the Fas pathway and PDX-1 has not been investigated.
In addition to its effect on β-cell turnover, hyperglycemia impairs β-cell secretory
function [2, 25–27]. This glucotoxic effect is evident before apoptosis leads to a
significant decrease in β-cell mass. This is most striking in vitro, where a 4-day ex-
posure of human islets to elevated glucose concentrations leads to almost complete
ablation of β-cell secretory function although less than 1% of β-cells are apoptotic
[8]. Since hyperglycemia regulates Fas expression [7, 9], we hypothesize that the
Fas pathway may not solely mediate glucose-induced changes in cell-turnover, but
also changes in β-cell secretory function.
2.2 Experimental Procedures
2.2.1 Animals
Ethical approval for mouse studies was granted by the Zu¨rich Cantonal Animal Ex-
perimentation Committee. C57BL/6j wildtype and mice with a natural Fas mutation
backcrossed for more than ten generations onto this same C57BL/6j inbred strain
background (B6.MRLlpr) were obtained from The Jackson Laboratory (Bar Harbor,
ME). NODβFas−/− and BL6βFas−/− mice were produced by introduction of LoxP
2.2. EXPERIMENTAL PROCEDURES 15
sites flanking exon IX of Fas and breeding to NOD and C57Bl/6 rat insulin promoter
(RIP)-Cre mice (A. V. C. et al., manuscript in preparation). The aly/aly (alymphopla-
sia or Map3k14aly) mice which carry a point mutation in the NFκB-inducing kinase
(NIK, encodec by Map3k14) were bred in-house [28]. Animals were housed at 22◦C
with a 12-h light-dark cycle (lights on at 07:00) and allowed free access to water and
chow.
2.2.2 Intra-peritoneal glucose and insulin tolerance tests
Mice were fasted 12 h overnight and injected intra-peritoneally with 1 or 2 mg/g
body weight glucose (40% glucose solution, Laboratorium Dr. G. Bichsel AG, In-
terlaken, Switzerland) or with 0.5 mU/g recombinant human insulin (Novo Nordisk
A/S, Bagsvrd, Denmark) for the glucose or insulin tolerance test, respectively. Blood
samples were obtained from tail-tip bleedings, and blood glucose concentrations
were measured with a Glucometer (Freestyle, Disetronic Med. Systems, Burgdorf,
Switzerland).
2.2.3 In situ pancreas perfusion
Mice starved overnight were anesthetized with sodium pentothal intra-peritoneally
and prepared for pancreas perfusion as previously described [29]. The pancreas was
perfused at 37◦C with 1.5 ml/min of modified Krebs-Ringer HEPES buffer supple-
mented with 2.8 mM glucose (basal) and with 16.7 mM glucose for stimulation. The
pancreatic effluent of the first 30 min of perfusion with basal glucose was not col-
lected. After this equilibration period, the effluent was collected in 1 min fractions
from a catheter placed in the portal vein. The insulin content of each fraction was
determined by radioimmunoassay [30].
2.2.4 Islet cell isolation and culture
Human islets were isolated from pancreata of organ donors at the University of
Geneva Medical Center and mouse islets were isolated as previously described [31].
The islets were cultured on extracellular matrix-coated plates derived from bovine
corneal endothelial cells (Novamed Ltd., Jerusalem, Israel), allowing the cells to
attach to the dishes and spread into a monolayer. Mouse islets were cultured in
RPMI 1640 medium containing 11.1 mM glucose, 100 U/ml penicillin, 100 µg/ml
streptomycin, 40 µg/ml gentamycin and 10% FCS (Invitrogen Ltd., Carlsbad, CA),
and human islets in CMRL 1066 medium containing 5.5 mM glucose, 100 U/ml
penicillin, 100 µg/ml streptomycin and 10% FCS, hereafter referred to as culture
medium. In some experiments, one day after plating the islets, the medium was
changed to culture medium containing 500 ng/ml mouse antagonistic anti-Fas anti-
body (ZB4; MBL, Nogoya, Japan), or 500 ng/ml mouse IgG isotype control (R&D
Systems Inc.). The initial characterisation of ZB4 was performed in Jurkat cells
[32]and was shown to be efficient in different human cell types including lympho-
cytes [33], endothelial cells [34], and β-cell [7]. The INS1E cell line was cultured
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in RPMI 1640 containing 11.1 mM glucose, 100 U/ml penicillin, 100 µg/ml strepto-
mycin, 40 µg/ml gentamycin and 10% FCS and beta mercaptoethanol.
2.2.5 Liposome-mediated transfection
Lipofectamine 2000-DNA complexes were prepared according to the manufacturer’s
instructions (Invitrogen Ltd.) using a RIP-FLAG-tagged-FLIP-long- (generously
provided by J. Tschopp, University of Lausanne, Switzerland) or RIP-plasmid-DNA
(control) or a CMV-Fas-plasmid-DNA (generously provided by S. Nagata, Osaka
University Medical School, Japan). The solution was added to the islets and INS1E
cell line (70% confluency) at a final concentration of 3 µg of DNA/ml. After 6 h
incubation, 2 ml culture medium was added to the islets, and after 24 h the medium
was aspirated and replaced with fresh culture medium. For the INS1E cell line, the
media was aspirated and replaced with fresh culture media after the 6 h incubation
period.
2.2.6 Immunostaining and histochemical analysis
The entire pancreas was rapidly resected from euthanized mice, all fat and non-
pancreatic tissue trimmed and the pancreas was weighed. The mean weight of the
pancreata did not differ between groups at any age. A longitudinal section of the pan-
creas (tail through head in the flat plane of the pancreas) was fixed in formaldehyde
adn then embedded in paraffin. Sections of pancreas were then taken through the
fixed tissue in the plane of embedding so that a near complete section of pancreas
(head, body and tail) through its maximal width was obtained with each section.
For insulin and glucagon double-labeling, paraffin embedded tissue sections were
incubated with guinea pig anti-insulin antibody (Dako, Carpinteria, CA) followed
by detection with a fluorescein-conjugated rabbit anti-guinea pig antibody (Dako).
Subsequently, the specimens were labeled for glucagon with mouse anti-glucagon
antibody (Dako), followed by detection with donkey anti-mouse Cy3-conjugated an-
tibody (Jackson ImmunoResearch Laboratories West Grove, PA). In digital images
of individual islets, the area of insulin immunopositive cells was traced manually and
computed using analySISTM 3.1 software (Soft Imaging System GmbH, Muenster,
Germany). The β-cell volume of each islet was estimated by using β-cell area and
by assuming spherical islets. After washing with PBS, cultured islets were fixed in
4% paraformaldehyde followed by permeabilisation with 0.5% triton X-100 and in-
cubation with mouse anti-Fas antibody (Transduction Laboratories, Lexington, KY).
Detection was performed using the streptavidin-biotin-peroxidase complex (Zymed).
2.2.7 Anti-nuclear antibodies
Anti-nuclear antibodies were detected by incubation of a mouse liver tissue sec-
tion with test serum followed by detection with anti-mouse Cy3-conjugated antibody
(Jackson). Serum of wildtype and of diseased mice was used as negative and positive
controls, respectively.
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2.2.8 Cytokine assay
Serum IL-1β, IFNγ, IL-6 and TNFα were measured using Luminex technology ac-
cording to the manufacturer’s instructions (Labodia, Pre´verenges, Switzerland).
2.2.9 Cell replication and apoptosis
For β-cell replication and apoptosis studies, islets were double stained with either
a monoclonal antibody against the mouse Ki-67 antigen (Zymed, San Francisco,
CA) or by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL) according to the manufacturer’s instructions (In Situ Cell Death Detec-
tion Kit, AP; Boehringer Mannheim, Germany) and for insulin as previously de-
scribed [35].
2.2.10 Insulin release, and insulin and ATP content
For acute insulin release in response to glucose, islets were washed and pre-incubated
(30 min) in Kreb’s Ringer bicarbonate buffer (KRB) containing 2.8 or 3.3 mM glu-
cose and 0.5% BSA. KRB was then replaced by KRB 2.8 or 3.3 mM glucose for
1 h (basal), followed by an additional 1 h in KRB 16.7 mM glucose or 2.8 mM
glucose and 20 mM leucine, 10 mM α-ketoglutarate dimethyl ester, 10 mM suc-
cinic acid dimethyl ester or a mixture of 10 µM forskolin and 100 µM 3-isobutyl-1-
methylxanthine (Sigma). Islets were extracted with 0.18 N HCl in 70% ethanol for
determination of insulin content. To determine total insulin content of the pancreas,
the tissue was homogenized in 1 ml 0.18 N HCl in 70% ethanol and left overnight at
4◦C. Insulin was determined using a human insulin RIA kit (CIS bio international,
Gif-Sur-Yvette, France), which has similar affinity for both mouse and human in-
sulin. For determination of islet ATP content, islets were cultured overnight and
preincubated for 30 min in KRB followed by a 10 min stimulation with 16.7 mM
glucose KRB. Islet-ATP content was quantified with a Bioluminescence-based kit
(Roche).
2.2.11 RNA extraction and quantitative reverse
transcription-PCR (RT-PCR)
We extracted total RNA from the cultured islets by using the Rneasy mini kit (Qia-
gen, Basel, Switzerland) and performed RT-PCR by using the SuperScript Double-
Stranded cDNA synthesis kit according to the manufacturer’s instructions (Life Tech-
nologies, Gibco, Gaithersburg, MD). For quantitative analysis, we used the Light
Cycler quantitative PCR system (Roche, Basel, Switzerland) with a commercial
kit (Light Cycler-DNA Master SYBR Green I; Roche). Mouse primers used were
5′TACGGGGTTTGTGAAAGGAG3′ and 5′CACATCATTCCCCAGGAAAC3′ (in-
sulin); 5′GAGGACCCGTACAGCCTACA3′ and 5′CGTTGTCCCGCTACTACGT-
T3′ (PDX-1); 5′CTAAATTTGGTTGCCCCAGA3′ and 5′CTCCCATTATGGAGC-
CTGAA3′ (FLIPL); 5′CAGCCAGCGCCCAGTACC3′ and 5′CAATGCGGACGGA-
GGCAAAGC3′ (UCP-2); 5′GTGGCAGTGATGGCATGGAC3′ and 5′CAGCACC-
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AGTGGATGCAGGG3′ (GAPDH); 5′AGAGTCGCGCTGGTAAGAAGC3′ and
5′CCCCAATGGTCTTGTCACTT3′ (Tubulin). Human primers used were 5′CTCT-
ACAATGGGCTGGTTGC3′ and 5′TTGGTATCTCCGACCACCTC3′ (UCP-2);
5′CCACCTTGGGACCTGTTTAG3′ and 5′TGATGCCAGAGGAAGAGGAG3′
(PDX-1); 5′GCTGGTAGAGGGAGCAGATG3′ and 5′CTCACACCTGGTGGAA-
GCTC3′ (insulin), 5′AGAGTCGCGCTGTAAGAAGC3′ and 5′TGGTCTTGTCA-
CTTGGCATC3′ (Tubulin); 5′AACAGCGACACCCACTCCTC3′ and 5′GGAGGG-
GAGATTCAGTGTGGT3′ (GAPDH).
2.2.12 Western Blot
Protein was extracted using an extraction buffer containing 20 mM Tris pH 7, 1%
Triton-X-100, 150 mM NaCl, and 10% glycerol. The following protease inhibitors
were added immediately before use: 200 µl protease inhibitor cocktail (Roche), 20 µl
Na3VO4, 20 µl NaF, 10 µl PMSF and 4 µl 0.5 M EDTA (pH 8). After extraction,
an aliquot was used for protein determination and the remainder was frozen at –
80◦C in sample buffer. 30 µg Protein was loaded on a NuPage gel (Invitrogen),
blocked for 1 hour in TBS-T containing 5% milk. The membrane was exposed to a
rat monoclonal antibody to FLIP (Dave-2, Alexis biochemicals), a rabbit anti-PDX-
1 antibody (kindly donated by H. Edlund) and a rabbit anti-Actin antibody (Santa
Cruz). The secondary antibody was a goat polyclonal anti-rat IgG HRP (Alexis
biochemicals), or a donkey anti-rabbit IgG HRP (Santa Cruz). The emitted light
was captured on Kodak Bio Max Film after the membrane was exposed to Lumilight
western blotting substrate (Roche).
2.2.13 RNA interference
RNAs of 21 nucleotides, designed to target FLIPlong (Silencer Pre-designed siRNA)
and scrambled siRNA were synthesized by Ambion (Austin, TE). siRNA was trans-
fected using SiPortAmineTM, and transfection efficiency estimated with cy3 la-
beled siRNA using SilenceTM siRNA Labeling Kit (Ambion), as described pre-
viously [36].
2.2.14 NF-κB activation
For the gene reporter assay, INS-1E cells were transiently transfected according to
the manufacturer’s instructions using Superfect (Qiagen, Hilden, Germany) and a
total of 1 µg plasmid DNA. NF-κB-dependent gene transcription was analysed with
0.4 µg of the PathDetect NFκB cis-Reporting System (Stratagene, San Diego, CA).
The luciferase reporter gene was selectively regulated by 5x synthetic NF-κB pro-
moter enhancer elements. In all gene reporter assays, cells were also transfected
with an empty vector (pcDNA3, Invitrogen) as control. The promoter activity was
analysed using the Dual-Luciferase Reporter Assay System (Promega) according to
the manufacturer’s instructions. For detection of specific activation of NF-κB com-
plex by the classical pathway and the non-classical pathway nuclear extraction was
performed as per the manufacturer’s instructions (Nuclear Extract Kit, Active Motif)
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followed by analysis with ELISA-based Kits, using attached oligonucleotides bind-
ing to a NF-κB consensus site and detected by an anti-p65 or p50 subunit antibody
and by an anti-Relb subunit antibody, according to the manufacturer’s instructions
(Trans-AMTM NFκB and Trans-AMTM NFκB Family, Active Motif).
2.2.15 Determination of glucose uptake
Glucose uptake measurements into isolated white adipocytes were carried out as de-
scribed previously [37]. Briefly, epididymal white adipose tissue was dissected and
adipocytes were isolated with collagenase in KRB containing 4% (w/v) fatty acid-
free BSA and filtered through a 250 µm nylon mesh. Adipocytes were washed twice
and resuspended in KRB 1% BSA. Cells were incubated for 60 min with or without
100 nM insulin in U-14C-glucose (final glucose concentration 1 mM). The reaction
was terminated by centrifugation through a layer of dinonylphthalate followed by
liquid scintillation counting.
2.2.16 Acute glucose stimulated insulin synthesis
For radiolabeling, batches of 120 to 220 islets from a single mouse pancreas were
washed in KRB-Hepes, 0.25% BSA (KRB-Hepes-BSA), 2.8 mM glucose and prein-
cubated for 15 min at 37◦C in this same buffer. The islets were resuspended in 100 µl
KRB-Hepes-BSA with either 2.8 or 16.7 mM glucose and containing 590 µCi/ml
[3H]leucine (specific radioactivity 150 Ci/mmol, American Radiolabeled Chemicals
Inc., St. Louis, MO). The islets were radiolabeled for 25 min at 37◦C. and the label-
ing stopped by addition of 0.9 ml ice-cold KRB-Hepes-BSA, 2.8 mM glucose, 1 mM
(unlabeled) leucine and washed 3x in this buffer. The islet pellet was extracted by
two cycles of freeze-thawing followed by sonication on ice in 200 µl 0.2 M glycine,
0.25% BSA, pH 8.8. The extracts were then centrifuged at 12,000 xg for 10 min to
remove particulate material and the supernatants kept frozen at –20◦C before anal-
ysis. Proinsulin and insulin were immunoprecipitated as described in detail previ-
ously [38]. In brief, duplicate samples of 50 µl aliquots of extracts from each islet
preparation were incubated with 20 µl guinea-pig anti-insulin serum that cross-reacts
with proinsulin (Sigma. MO, binding capacity more than 10-fold higher than total
immunoreactive insulin in the 50 µl aliquot) and antibody-bound products then pre-
cipitated with protein-A Sepharose. Non-specific binding was measured in parallel
using a single extract aliquot of 50 µl and without anti-insulin serum. Radioactivity
was measured in a liquid scintillation counter (ReadyFlow III from Beckman Coul-
ter, Fullerton, CA).
2.2.17 Statistical analysis
Samples were evaluated in a randomized manner by a single investigator (D. S.) blind
to the treatment conditions. Data are presented as means ± SE and were analyzed by
Student’s t-test or by analysis of variance with a Bonferroni correction for multiple
group comparisons.
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2.3 Results
2.3.1 Fas regulates β-cell function
To assess the role of Fas on β-cell secretory function, we first used mice with a nat-
ural Fas mutation (lpr [39]) transferred onto a C57BL/6j inbred strain background.
In contrast to the original MRL/MpJlpr mice, that have an onset of a systemic lupus
erythematosus-like autoimmune-disease at 8 weeks of age, the B6.MRLlpr mice do
not develop any detectable sign of autoimmunity even at 13 weeks of age as de-
scribed previously [40]. This was confirmed by the lack of detectable morphological
and histological changes in the spleen, liver, kidney, lung and lymph nodes, as well
as by the failure to detect circulating anti-nuclear antibodies or increased circulating
cytokine (IL-1β, IFNγ, IL-6 and TNFα) levels in Fas deficient mice between 7 to 13
weeks of age. At 8 weeks of age, Fas deficient B6.MRLlpr mice displayed impaired
glucose tolerance after an intra peritoneal glucose load (Fig. 2.1 A & B). Normal
sensitivity of the Fas deficient mice to injected insulin (Fig. 2.1 C), as well as unal-
tered insulin-stimulated glucose uptake in adipose tissue (Fig. 2.1 D), ruled out the
possibility that insulin resistance was responsible for the impaired glucose tolerance.
Accordingly, fasting (12h) circulating insulin (0.59 ± 0.15 and 0.58 ± 0.11 ng/ml
for wildtype and Fas deficient, respectively) and glucagon (76 ± 19 and 77 ± 15
pg/ml) levels were unchanged. When measuring insulin secretion during the glucose
tolerance test, baseline circulating insuin was higher in Fas deficient mice, but did
not increase in response to the glucose load, whereas in wildtype mice there was a
significant increase (Fig. 2.1 E). To exclude a non-specific effect related to the ge-
netic background or an indirect effect due to Fas-deficiency in non-β-cells, a second
set of glucose tolerance tests was performed on mice with a β-cell-specific knock-
out of Fas. Since these mice are on the NOD genetic background, care was taken
to analyze the animals at 6 weeks of age, before the onset of insulitis. Compared
to their wildtype NODβFas+/+ littermates, heterozygous NODβFas+/− showed a
slight, albeit non-significant impairment of glucose tolernace, whereas the homozy-
gous NODβFas−/− mice displayed a significantly impaired glucose tolerance, thus
confirming the selective effect of Fas deficiency (Fig. 2.1 F). Finally, the conse-
quence of Fas deficiency was confirmed by a third animal model, i./e./ in mice with
a β-cell-specific knockout of Fas on a C57Bl/6 genetic background (Fig. 2.1 G &
H).
To characterize the defect in insulin secretion, we performed in situ pancreas per-
fusion experiments. In Fas deficient mice, the first phase insulin secretory response
to a 15 min perfusion of 16.7 mM glucose was delayed and blunted, followed by
an ablation of second phase insulin release (Fig. 2.1 I & J). The secretory defect
apparent in the Fas deficient mouse pancreas was also present in isolated islets. In-
deed, the ratio of high to low glucose-stimulated insulin release was 45% less than
in wildtype islets (Fig. 2.1 K). The defect was also apparent in islets after 24 hours
of culture (2-fold less glucose stimulated insulin secretion in the Fas deficient islets).
The basal secretion was elevated in Fas deficient islets which is in agreement with
the in vivo levels of insulin secretion and may reflect the compensatory increase in
islet β-cell mass due to defective secretion. The role of Fas in glucose-stimulated
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insulin secretion was also verified in human islets by means of the antagonistic anti-
Fas antibody ZB4. In cultured human islets isolated from pancreata of organ donors,
ZB4 inhibited glucose-stimulated insulin release already after 6 hours (Fig. 2.1 L),
whereas it was enhanced by FasL after 48 hours (Fig. 2.1 M), supporting the notion
that Fas activation is necessary for normal β-cell function.
Immunohistochemical evaluation of pancreata from 8 week old Fas deficient mice
revealed a normal islet structure and ratio of β to α-cells. However, islet β-cell
mass was dramatically increased as compared to wildtype mice (2.10 ± 0.48 mg in
Fas deficient vs. 0.59 ± 0.15 mg in wildtype mice, p < 0.01), with no change in
pancreas weight (0.27 ± 0.02 g in Fas deficient vs 0.22 ± 0.01 g in wildtype mice).
Despite the approximately threefold increase in islet β-cell mass of Fas deficient
mice, insulin content per pancreatic wet weight and per isolated islet, remained un-
changed (not shown), probably due to a severe decrease in insulin mRNA per β-cell
(Fig. 2.2 A). In parallel, expression of PDX-1 was decreased at mRNA and protein
level (Fig 2.2 A & B) whereas uncoupling protein 2 (used as a control) was not sig-
nificantly changed (Fig. 2.2 A). Similarly, in cultured human islets, the antagonistic
anti-Fas antibody ZB4 inhibited insulin and PDX-1 mRNA expression, demonstrat-
ing a direct regulation of these genes by Fas (Fig. 2.2 C). Furthermore, expression
levels of FLIP mRNA were similar in Fas deficient and wildtype mice (not shown).
To characterize the secretory pathway regulated by Fas signaling, insulin release
was stimulated with metabolic secretagogues, generating mitochondrial coupling
factors such as ATP. The energy substrates, leucine as well as the cell permeable
dimethyl esters of α-ketoglutarate and succinic acid, were less effective in stimulat-
ing insulin release from Fas deficient mice and ZB4-treated human islets (Fig. 2.2 D
& E). In contrast, the secretory responses in Fas deficient or ZB4-treated islets
were restored in the presence of the phosphodiesterase inhibitors forskolin and 3-
isobutyl-1-methylxanthine (IBMX) that increase cAMP levels (Fig. 2.2 D & E). Fur-
thermore, acute glucose stimulated insulin synthesis (that reflects translation) was
normal (Fig. 2.2 F). This suggests that the exocytotic machinery and insulin trans-
lation are fully functional in the absence of Fas-signaling, and indicates a defect in
the stimulus-secretion coupling in addition to persistently decreased insulin mRNA
expression and insulin content. Consistent with this hypothesis, ATP concentration
was decreased in Fas deficient and ZB4-treated islets (Fig. 2.2 G & H).
2.3.2 Fas and FasL are expressed in islets and regulate
insulin and PDX-1 mRNA expression
FasL and, at low levels, the Fas receptor are normally expressed in β-cells, as pre-
viously shown in human islets and in the present study in mouse islets [[7, 10] and
Fig. 2.3 A–D]. To examine whether the effects of the Fas pathway indeed influence
the phenotype of the β-cell, wildtype and Fas deficient mouse islets were transfected
with a vector encoding Fas (Fig. 2.3 C & D). Transfection efficiency in β-cell mono-
layers was approximately 30–50% (Fig. 2.3 D). Restoration of Fas in Fas deficient
islets significantly stimulated insulin and PDX-1 mRNA expression whereas overex-
pression of Fas at similar levels in wildtype mouse islets did not affect these genes,
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Figure 2.1: Fas regulates β-cell secretory function. Blood glucose levels following i.p. in-
jection of (A) 2 mg glucose and (B) 1 mg glucose / g body weight in male Fas deficient
B6.MRLlpr and wildtype C57BL/6j mice aged 7–8 weeks. * indicates p < 0.05, Fas defi-
cient versus wildtype; n = 15 and 10 for each group in (A) and (B), respectively. (C) Blood
glucose levels following i. p. injection of insulin in male Fas deficient and wildtype mice. *
indicates p < 0.05, Fas deficient vs. wildtype; n = 15 for each group. (D) Insulin-stimulated
2-Deoxyglucose uptake in adipocytes isolated from Fas deficient and wildtype mice. Data
are the means of 2 separate experiments, each in hexaplicates. (E) Insulin levels follow-
ing i.p. injection of 2 mg glucose / g body weight in male Fas deficient and wildtype mice;
n = 15 for each group. * indicates p < 0.05 relative to wildtype and # indicates p < 0.05
relative to timepoint 0 and 2 min. (F & G) Blood glucose levels following i.p. injection
of glucose in (F) male prediabetic NODβFas−/− (homozygous), NODβFas+/− (heterozy-
gous), and NODβFas+/+ (wildtype) littermate mice aged 5–6 weeks,* indicates p < 0.05,
NODβFas−/− vs. NODβFas+/+, n = 7, 5 and 10, respectively for each group and in (G)
male BL6βFas−/− (Fas Knockout) and BL6βFas+/+ (wildtype) littermate mice aged 9–10
weeks. * indicates p < 0.05, n = 12 and 5 for each group, respectively . (H) Blood glu-
cose levels following i.p. injection of insulin in male Fas knockout and wildtype littermate
mice. * indicates p < 0.05, n = 16 and 4 for each group, respectively. (I & J) Glucose
induced insulin secretion in perfused pancreata from Fas deficient and wildtype mice. Pan-
creata were perfused with basal solution (2.8 mM glucose) for 30 min before perfusate was
collected (from time 0). Glucose was increased to 16.7 mM glucose for the indicated period.
First phase insulin secretion for wildtype mice was calculated from min 16 to 20, and for
Fas deficient mice from min 17 to 25. Second phase insulin secretion for wildtype mice was
calculated from min 20 to 30 and for Fas deficient mice from min 25 to 30. Data is the mean
of 3 separate animals for each group. (K) Percentage of islet insulin content released during
successive 1 h incubation at (basal) 3.3 mM and (stimulated) 16.7 mM glucose following an
8 day culture period of islets isolated from Fas deficient and wildtype mice, and (right panel)
the corresponding stimulatory index of insulin secretion. Data are the means of 4 separate
experiments, each in hexaplicate. Insulin content for wildtype mice was 19.77± 2.71 pMol
and for Fas deficient mice, 24.75 ± 4.50 pMol. * indicates p < 0.001. (L) Percentage of
islet insulin content released during successive 1 h incubation at (basal) 3.3 and (stimulated)
16.7 mM glucose following a 6 hour and 4 day incubation period of islets isolated from hu-
man pancreata in the presence of 500 ng/ml isotype IgG (control) or 500 ng/ml antagonistic
anti-Fas antibody (ZB4), and (right panel) the corresponding stimulatory index of insulin se-
cretion. Data are the means of 3 separate experiments, each in triplicate. Insulin content for
control islets was 6.12± 2.41 and 4.50± 0.26 pMol and for ZB4-treated islets, 7.92± 1.50
and 4.43 ± 0.79 pMol after 6 hours and 4 days. * indicates p < 0.001. (M) Percentage
of islet insulin content released during successive 1 h incubations at basal and stimulated
glucose following incubation of human islets in the presence of FasL for 48 hours. Insulin
content for control was 6.12 ± 2.41 and for FasL-treated islets 9.65 ± 2.02 pMol. Data are
the means of 2 separate experiments, each done in quintaplicate.
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Figure 2.2: (A) Quantitative RT-PCR detection of insulin, PDX-1 and uncoupling protein 2
(UCP-2) mRNA expression. Total RNA was isolated from Fas deficient and wildtype islets.
The level of mRNA expression was normalized to GAPDH and the results expressed as per-
centage of wildtype islet mRNA levels; n = 5 for each group. * denotes p < 0.05. (B)
Immunoblotting of PDX-1 and Actin. Protein was isolated from Fas deficient and wildtype
islets, and from the 3T3 cell-line (negative control). One of two experiments is shown.
(C)Quantitative RT-PCR detection of insulin, PDX-1 and uncoupling protein 2 (UCP-2)
mRNA expression. Total RNA was isolated from human islets cultured for 4 days in the
presence of 500 ng/ml isotype IgG (control) or 500 ng/ml antagonistic anti-Fas antibody
(ZB4). The level of mRNA expression was normalized to GAPDH and the results expressed
as percentage of control islet mRNA levels. Data are the means of 3 separate experiments,
each in duplicate. (D & E) Stimulatory index of insulin secretion during successive 1 h incu-
bation at (basal) 3.3 mM glucose and (stimulated) 16.7 mM glucose, 20 mM leucine, 10 mM
α-ketoglutarate dimethyl ester (α-Ketoester), 10 mM succinic acid dimethyl ester (SAD), or
10 M forskolin and 100 M IBMX (F/I), (D) following a 4 day culture period of islets isolated
from Fas deficient and wildtype mice and (E) after a 4 day culture period of human islets
from 3 different donors in the presence of 500 ng/ml isotype IgG (control) or 500 ng/ml
antagonistic anti-Fas antibody (ZB4). Data are the means of 3 separate experiments, each in
triplicate. * indicates p < 0.05 vs. wildtype or controls. (F) Islets isolated from wildtype
and Fas deficient mice were radiolabeled (25 min) wiht [3H]-Leucine in 2.8 mM (basal) and
16.7 mM (stimulated) glucose. Radiolabeled proinsulin plus insulin is presented as specifi-
cally immunoprecipitable radioactivity as a function of islet number (cpm/100 islets). Data
represent the means of 3 separate animals per group. (G) After 1 day in culture, islets iso-
lated from Fas deficient and wildtype mice were incubated successively for 30 min in 2.8 mM
glucose followed by an additional 10 min in 16.7 mM glucose and analyzed for stimulated
ATP content. * indicates p < 0.001. Data are means of percentage relative to control for 3
separate experiments, each in triplicate. (H) After a 4 day culture period, human islets cul-
tured in the presence of 500 ng/ml isotype IgG (control) or 500 ng/ml antagonistic anti-Fas
antibody (ZB4), were incubated successively for 30 min in 2.8 mM glucose followed by an
additional 10 min in 16.7 mM glucose and analysed for stimulated ATP-content. * indicates
p < 0.05. Data are means of percentage relative to control for islets from 3 different donors,
each plated in triplicate.
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Figure 2.3: Fas and FasL are expressed in mouse islets and regulate insulin and PDX-
1 mRNA expression. RT-PCR analysis of (A) FasL and (B) Fas expression in wildtype
and Fas deficient islets. Each lane represents an individual animal. GAPDH was used as
control. (C–F) Fas deficient and wildtype islets were transfected with a vector encoding for
Fas and incubated for 8 days: (C) RT-PCR of Fas and GAPDH (control) expression in Fas
deficient and wildtype islets; (D) Immunostaining for Fas; Quantitative RT-PCR detection of
(E) insulin and (F) PDX-1 mRNA expression normalized to GAPDH. n = 3 for each group.
* denotes p < 0.05 relative to wildtype and # relative to Fas deficient control.
possibly because endogenous Fas was sufficient to maximally stimulate steady-state
PDX-1 levels (Fig. 2.3 E & F).
2.3.3 FLIP regulates insulin and PDX-1 mRNA expression
via the alternative pathway of NF-κB
Next we investigated the mediators of Fas regulating insulin production. Transfec-
tion efficiency of FLIP in β-cell monolayers was approximately 30–50%, as pre-
viously shown [14]. Overexpression of FLIP significantly increased islet insulin
and PDX-1 mRNA and protein expression accompanied by increased insulin con-
tent (Fig. 2.4 A, B & C). Next we tested whether FLIP can also regulate insulin
production in Fas deficient mouse islets. As expected, transfection of FLIP in Fas
deficient islets enhanced islet insulin content by 63 ± 24% (n = 3, p = 0.05). The
functional role of FLIP in β-cell maturation was then investigated by RNA inter-
ference (siRNA). siRNA to FLIP suppressed endogenous FLIP expression by 70%
leading to a 50% decrease in insulin and PDX-1 expression with a concomitant de-
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crease in insulin content (Fig. 2.4 D) whereas scrambled siRNA had no effect on
these genes (not shown). Beta-cell proliferation and apoptosis remained unaffected
by transfection with FLIP at baseline 11.1 mM glucose (not shown), in support of
the concept that Fas-FLIP can affect β-cell function independently of changes in
cell turnover. To test whether FLIP acts via NF-κB, INS-1E cells were transfected
with an NF-κB-driven Luciferase construct. Co-transfection with FLIP strongly in-
duced NF-κB activity, reaching similar levels to IL-1β (Fig. 2.4 E). Nevertheless,
detection of p50-RelA (p65) binding to an NF-κB consensus site revealed no sig-
nificant change following transfection with FLIP (Fig. 2.4 F). However, using an
anti-RelB antibody which detects binding to an NF-κB consensus site, revealed a
robust induction of RelB by FLIP, indicating NF-κB activation via the alternative
pathway (Fig. 2.4 G). To support these results, we used islets isolated from aly/aly
mice, which are defective in activation of the alternative NF-κB pathway because of
a mutation in NIK [41]. In contrast to wildtype islets, in aly/aly mice, FLIP failed to
induce insulin and PDX-1 mRNA expression (Fig. 2.4 H & I). Finally, aly/aly mice
displayed impaired glucose tolerance (Fig. 2.4 J), supporting the concept that NF-κB
activity is required for β-cell secretory function [16].
2.4 Discussion
Hitherto, activation of the Fas receptor, was thought to mainly activate the apop-
totic cascade. Recently we have shown that in human β-cells FLIP may switch
Fas-signaling towards proliferation [14]. Here we demonstrate that Fas is also a reg-
ulator of β-cell function. This is supported by impaired glucose tolerance in Fas
deficient animals, and by an abnormal response to glucose in perfused pancreata
and in isolated islets. In particular, impaired β-cell function in the perfused pan-
creas was characterized by a delayed and reduced first and second phase of insulin
secretion. As shown in isolated islets, this defect is explained by decreased ATP
synthesis, and suggests a mitochondrial defect. Indeed, decreased total cellular ATP
mainly reflects overall mitochondrial dysfunction [42]. This notion is supported by
the failure of energy substrates generating mitochondrial coupling factors to produce
a normal insulin release. In contrast, non-fuel stimuli evoked normal insulin secre-
tion, suggesting that metabolism-secretion coupling is defective in the absence of
Fas-signaling while the exocytotic machinery is fully functional.
The defective metabolism-secretion coupling may be a consequence of decreased
PDX-1 expression. PDX-1 has recently been shown to be an essential regulator of
several events in insulin secretion, including mitochondrial metabolism and in par-
ticular ATP production [19, 21]. In line with these findings, we observed a decrease
in PDX-1 expression in the islets of Fas deficient animals. Moreover, FLIP upreg-
ulation increased insulin and PDX-1 expression. Interestingly, mutations in PDX-1
have been associated with type 2 diabetes [43, 44] and high glucose dramatically
lowers DNA-binding activity of PDX-1 [45].
Nonobese diabetic (NOD) mice develop spontaneous autoimmune diabetes, but
Fas deficient NOD mice are protected against the disease [46–49]. Therefore, Fas
has been postulated to play an important role in the β-cell demise in type 1 diabetes.
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Figure 2.4: INS-1E (A, E–G), wildtype and aly/aly mouse islet (B–D,H,I) cells were trans-
fected with a mock or a vector encoding for FLIP (FLIP transfected), or exposed to siRNA to
FLIP. (A) Immnunoblotting of FLIP. (B, D) Quantitative RT-PCR detection of insulin, PDX-
1 and FLIP mRNA expression, and islet insulin content. The level of mRNA expression was
normalized to tubulin or GAPDH and the results expressed as mRNA levels relative to con-
trols. (C) Immunoblotting of PDX-1 in islets and in 3T3 cells (negative control) transfected
with the RIP vector alone an dwith RIP-FLIP. One of two experiments is shown. Analysis
of NF-κB activity by (E) detection of Luciferase activity following transfection of an NF-
κB-driven Firefly Luciferase construct normalized to a co-transfected constitutive Renilla
Luciferase construct, and by detection of (F) p50-p65 and (G) RelB binding to an NF-κB
consensus site. The effect of FLIP was compared to 150 pg/ml IL-1β. Data is a mean of 4
separate experiments each in duplicate. Quantitative RT-PCR detection of (H) insulin and
(I) PDX-1 mRNA expression normalized to GAPDH. n = 3–4 independent experiments. *
denotes p < 0.05 relative to wildtype controls and # p < 0.05 relative to aly/aly controls.
(J) Blood glucose levels following an i. p. injection of glucose (2 mg/g body weight) in
male homozygous and heterozygous aly/aly mice and C57Bl/6 (wildtype) mice. * indicates
p < 0.05 homozygous, heterozygous vs wildtype, n = 6, 5 and 5 respectively for each
group. (K) Hypothetical model illustrating the consequence of hyperglycaemia on β-cell
production of IL-1β in parallel wiht insulin secretion. The paracrine effect of IL-1β induces
Fas engagement, which in the presence of FLIP leads to β-cell proliferation, differentiation
and increased function.
However, a direct role of Fas in β-cell destruction has been challenged [50, 51].
Possibly, some of these discrepancies can be explained by the physiological role of
Fas. Indeed, deletion of Fas will protect from cytokine-induced cell death but it will
also impair the normal insulin secretory function as shown in the present study.
The endocrine pancreas has a remarkable capacity to adapt to conditions of in-
creased insulin demand, such as in obesity and pregnancy, by increasing its func-
tional β-cell mass [1]. Taken together with previous findings we propose a hy-
pothesis for long-term β-cell plasticity, attributing a central role to the Fas pathway
(Fig. 2.4 K). According to this hypothesis, long-term adaptation of theβ-cells to con-
ditions of increased demand may be triggered by hyperglycaemic excursions [52].
These excursions elicit β-cell production of IL-1β [8] followed by Fas upregulation
[7, 9]. At low concentrations of IL-1β and in the presence of FLIP, Fas engagement
leads to β-cell proliferation [53] and enhanced function via NFκB and PDX-1, as
shown in the present study.
The contribution of insufficient insulin secretion to the development of type 2 dia-
betes is now widely accepted [1–3]. However, opinions diverge regarding the relative
contribution of a decrease in β-cell mass versus an intrinsic defect in the secretory
machinery of the β-cell. Here we demonstrate that the Fas pathway regulates β-cell
secretory function in addition to its known role in β-cell-turnover. It follows that
the adaptive mechanisms of function and mass share common regulatory pathways
and will therefore act in concert. However, β-cell adaptation is not solely dependent
upon the Fas pathway since Fas deficient animals exhibited a compensatory increase
in β-cell mass. Nevertheless, the results support a novel role for the Fas pathway in
regulating β-cell secretory function.
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Abstract
High glucose concentrations have a dual effect on β-cell turnover, inducing
proliferation in the short-term and apoptosis in the long-term. Hyperglycemia
leads to β-cell production of IL-1β in human pancreatic islets. Fas, a death
receptor regulated by IL-1β, is involved in glucose-induced β-cell apoptosis.
Fas engagement can be switched from a death signal to induction of prolif-
eration when the caspase-8 inhibitor FLIP is active. Here we show that IL-
1β at low concentrations may participate in the mitogenic actions of glucose
through the Fas-FLIP pathway. Thus, exposure of human islets to low IL-1β
concentrations (0.01–0.02 ng/ml) stimulated proliferation and decreased apop-
tosis whereas increasing amounts of IL-1β (2–5 ng/ml) had the reverse effects.
A similarly bimodal induction of FLIP, PDX-1 and Pax4 mRNA expression as
well as glucose-stimulated insulin secretion was observed. In contrast, Fas in-
duction by IL-1β was monophasic. Low IL-1β also induced the IL-1 receptor
antagonist (IL-1Ra), suppression of which by RNA interference abrogated the
beneficial effects of low IL-1β. The Fas antagonistic antibody ZB4 and siRNA
to FLIP prevented low IL-1β-stimulated β-cell proliferation. Consistent with
our in vitro results, IL-1β knockout mice displayed glucose intolerance along
with a decrease in islet Fas, FLIP, Pax4 and PDX-1 transcripts. These findings
indicate that low IL-1β levels positively influence β-cell function and turnover
through the Fas-FLIP-pathway, and that IL-1Ra production prevents harmful
effects of high IL-1β concentrations.
3.1 Introduction
The capacity of the pancreatic β-cell to adaptively increase insulin secretion in re-
sponse to long term insulin resistance (for example in obesity) is fundamental to
the maintenance of normoglycemia; failure of such a response results in diabetes
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[1–8]. Changes in glucose concentration are key regulators of β-cell secretory func-
tion. Short-term exposure of human islets to increased glucose concentrations will
enhance insulin production and β-cell proliferation, while prolonged exposure will
have toxic effects leading to impaired insulin secretion and β-cell apoptosis [9–17].
Various mechanisms for this glucotoxic effect have been proposed, including ad-
vanced glycation end products, reactive oxygen species, impairment of insulin gene
transcription and ER-stress. Recently, IL-1β was shown to be induced in β-cells of
patients with type 2 diabetes indicating that the cytokine could be an important me-
diator contributing to glucotoxicity [18]. Consistent with the latter, β-cell expression
of IL-1β correlates with appearance of hyperglycemia in several animal models of
diabetes including the Psammomys obesus, the OLEFT rat, the GK rat and the hu-
man islet amyloid polypeptide transgenic rat [18–21, and Peter C. Butler, personal
communication]. IL-1β has been shown to impair insulin release and to induce Fas
expression enabling Fas-triggered apoptosis in rodent and human islets [16, 22–31].
Accordingly, increased glucose concentrations also induce β-cell expression of Fas
in vitro and in vivo which will then be activated by the endogenous Fas ligand (FasL)
[16, 28, 32, 33].
Interestingly, the beneficial short-term effects of high glucose on β-cell function
and proliferation are also partly mediated by Fas. Indeed, in the presence of the
caspase-8 inhibitor FLIP, Fas signalling switches from apoptosis to cell replication
[34]. Furthermore, recently we demonstrated an additional role for the Fas pathway
in regulating insulin production and release [35]. Additionally, low concentrations
of IL-1β stimulate insulin release in rat islets [36]. Since glucose induces IL-1β, we
hypothesized that IL-1βmay also mediate beneficial effects of glucose. We show that
low concentrations of IL-1β induce β-cell proliferation and enhance β-cell secretory
function via the Fas-FLIP pathway, an effect facilitated by the concomitant IL-1Ra
production.
3.2 Research design and methods
3.2.1 Animals
Ethical approval for mouse studies was granted by the Zu¨rich Cantonal Animal Ex-
perimentation Committee. C57BL/6j wildtype (WT) mice were obtained from The
Jackson Laboratory (Bar Harbor, ME). IL-1β knockout (ILKO mice, on a C57BL/6j
background, were produced by gene targeting as described previously [37]. Animals
were housed at 22◦C with a 12 h light-dark cycle (lights on at 07:00) and allowed
free access to water and chow.
3.2.2 Intra-peritoneal glucose and insulin tolerance tests
Mice were fasted 12 h overnight and injected intra-peritoneally with 2 mg/g body
weight glucose (40% glucose solution, Laboratorium Dr. G. Bichsel AG, Interlaken,
Switzerland) or with 0.75 mU/g recombinant human (rh) insulin (Novo Nordisk
A/S, Bagsværd, Denmark) for the glucose or insulin tolerance test, respectively.
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Blood samples were obtained from tail-tip bleedings, and blood glucose concen-
tration was measured with a Glucometer (Freestyle, Disetronic Medical Systems,
Burgdorf, Switzerland).
3.2.3 Islet isolation and culture
Human islets were isolated from pancreata of nine organ donors at the University of
Geneva Medical Center and at the University of Illinois at Chicago. Mouse islets
were isolated as previously described [38]. The islets were cultured on extracel-
lular matrix-coated plates derived from bovine corneal endothelial cells (Novamed
Ltd., Jerusalem, Israel), allowing the cells to attach to the dishes and spread. Human
islets were cultured in CMRL 1066 medium containing 5.5 mM glucose and mouse
islets in RPMI 1640 medium containing 11.1 mM glucose, both supplemented with
100 U/ml penicillin, 100 µg/ml streptomycin and 10% FCS (Invitrogen Ltd., Carls-
bad, CA), hereafter referred to as culture medium. Two days after plating, when
most islets were attached and began to flatten, the medium was changed to culture
medium containing 5.5, 11.1 or 33.3 mM glucose with or without 0.01–5 ng/ml
rh IL-1β, 500 ng/ml rhIL-1Ra (R&D Systems Inc., Minneapolis, MN), 500 ng/ml
antagonistic Fas antibody (ZB4; MBL, Nogoya, Japan) or transfected as described
below.
3.2.4 RNA interference
RNAs of 21 nucleotides, designed to target human IL-1Ra (5′AUCUGCAGAG-
GCCUCCGCAtt3′/5′UGCGGAGGCCUCUGCAGAUtt3′), human FLIPL (Silencer
Pre-designed siRNA) and scrambled siRNA were synthesized by Ambion (Austin,
TE). siRNA was transfected using SiPortAmineTM, and transfection efficiency esti-
mated with cy3 labeled siRNA using SilenceTM siRNA Labeling Kit (Ambion), as
described previously [39].
3.2.5 Beta-cell replication and apoptosis
For β-cell proliferation studies, a monoclonal antibody against the human (Zymed
Laboratories Inc., San Francisco, CA) or mouse Ki-67 antigen (Santa Cruz Biotech-
nology Inc., Santa Cruz, CA) were used. The free 3′-OH strand breaks resulting
from DNA degradation were detected by the terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) technique according to the manufac-
turer’s instructions (In Situ Cell Death Detection Kit, AP; Boehringer, Mannheim,
Germany) and as described previously in detail [14, 18]. Thereafter, islets were incu-
bated for 30 minutes at 37◦C with a guinea pig anti-insulin antibody (Dako, Carpin-
teria, CA), followed by detection using the streptavidin-biotin-peroxidase complex
(Zymed) or a fluorescein-conjugated rabbit anti-guinea pig antibody (Dako).
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3.2.6 Histochemical analysis
The pancreata were weighed, fixed in formalin and embedded in paraffin. Ten repre-
sentative sections from each pancreas (spanning the width of the pancreas) were used
in the analysis of β-cell mass. Tissue sections were deparaffinized, rehydrated and
incubated with guinea pig anti-insulin antibody (Dako) followed by detection with
a fluorescein-conjugated rabbit anti-guinea pig antibody (Dako). Subsequently, the
specimens were labeled for glucagon with mouse anti-glucagon antibody (Dako),
followed by detection with donkey anti-mouse Cy3-conjugated antibody (Jackson
ImmunoResearch Laboratories, West Grove, PA). Beta cell mass was analyzed us-
ing OpenlabTM software. The relative area of β-cells (green fluorescence) was de-
termined by quantification of the cross-sectional β-cell area divided by the cross-
sectional area of total tissue. The β-cell mass per pancreas was estimated as the
product of the relative cross-sectional area of β-cells per total tissue and the weight
of the pancreas. For detection of FLIP expression in β-cells, islets were fixed in 4%
paraformaldehyde, permeabilized with 0.5% Triton X-100, incubated with rabbit
anti-FLIP (R&D) followed by detection with donkey anti-rabbit Cy3-conjugated an-
tibody (Jackson). Subsequently the specimens were stained for insulin as described
above.
3.2.7 Western blot analysis
Equivalent amounts of protein from each treatment group were run on 15% SDS
polyacrylamide gels. Proteins were electrically transferred to nitrocellulose filters
and incubated with rabbit anti Caspase 8 (Stressgen, Victoria, BC, Canada), rab-
bit anti-human FLIPL (R&D), rabbit anti PDX-1 (kindly provided by Stefan Zahn,
NovoNordisk, Bagsvrd, Denmark) or rabbit anti-actin (Cell signaling, Beverly, MA)
antibodies followed by incubation with anti-rabbit IgG peroxidase-conjugated an-
tibodies (Santa Cruz Biotechnology Inc.). Immune complexes were detected by
chemiluminescence using LumiGLO (Cell Signalling).
3.2.8 RNA extraction and quantitative reverse
transcription-PCR (RT-PCR)
Total RNA was extracted from the cultured islets by using the Rneasy mini kit (Qi-
agen, Basel, Switzerland) and RT-PCR was performed by using the SuperScript
Double-Stranded cDNA synthesis kit according to the manufacturer’s instructions
(Life Technologies, Gibco, Gaithersburg, MD). For quantitative analysis, we used
the Light Cycler quantitative PCR system (Roche, Basel, Switzerland) with a com-
mercial kit (Light Cycler-DNA Master SYBR Green I; Roche). Mouse primers
used were 5′TACGGGGTTTGTGAAAGGAG3′ and 5′CACATCATTCCCCAGGA-
AAC3′ (insulin); 5′GAGGACCCGTACAGCCTACA3′ and 5′CGTTGTCCCGCTA-
CTACGTT3′ (PDX-1); 5′CTAAATTTGGTTGCCCCAGA3′ and 5′CTCCCATTA-
TGGAGCCTGAA3′ (FLIPL); 5′GCTCTTTTTGCCTGGGAGATC3′ and 5′CCCG-
AAGGACTCGATTGATAGA3′ (PAX4); 5′TATCAAGGAGGCCCATTTTG3′ and
5′GGTCAGGGTGCAGTTTGTTT (Fas); 5′GTGGCAGTGATGGCATGGAC3′ and
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5′CAGCACCAGTGGATGCAGGG3′ (GAPDH). Human primers used were 5′CCA-
CCTTGGGACCTGTTTAG3′ and 5′TGATGCCAGAGGAAGAGGAG3′ (PDX-1);
5′CCACCGGAATCGGACTATCTT3′ and 5′TACTGCCCACGCTGGAACTC3′
(PAX4); 5′GAGCAAGCCCCTAGGAATCT3′ and 5′GCCCTGAGTGAGTCTGAT-
CC3′ (FLIPL); 5′CTACCTAGTGTGCGGGGAAC3′ and 5′GCTGGTAGAGGGAG-
CAGATG3′ (insulin); 5′GCATCTGGACCCTCCTACCT3′ and 5′CAGTCTGGTT-
CATCCCCATT3′ (Fas); 5′AGAGTCGCGCTGTAAGAAGC3′ and 5′TGGTCTT-
GTCACTTGGCATC3′ (Tubulin); 5′AACAGCGACACCCACTCCTC3′ and 5′GG-
AGGGGAGATTCAGTGTGGT3′ (GAPDH), 5′TACGGGTCCTGGCATCTTGT3′
and 5′CCATTTGTGTTGGGTCCAGC3′ (Cyclophilin).
3.2.9 Insulin and IL-1Ra release, and insulin content
For acute insulin release in response to glucose, islets were washed and pre-incubated
(30 min) in Kreb’s Ringer bicarbonate buffer (KRB) containing 2.8 mM glucose and
0.5% BSA. KRB was then replaced by KRB 2.8 mM glucose for 1 h (basal), fol-
lowed by an additional 1 h in KRB 16.7 mM glucose. Islets were extracted with
0.18 N HCl in 70% ethanol for determination of insulin content. To determine to-
tal insulin content of the pancreas, the tissue was homogenized in 1 ml 0.18 N HCl
in 70% ethanol and left overnight at 4◦C. Insulin was determined using a human
insulin RIA kit (CIS bio international, Gif-Sur-Yvette, France), which has similar
affinity for both mouse and human insulin. Serum insulin was measured using Lu-
minex technology according to the manufacturer’s instructions (Linco Research Inc.
St. Charles, MO). IL-1Ra release in the islet supernatant was measured by using
human anti-IL-1Ra ELISA kits (R&D).
3.2.10 Statistical analysis
Samples were evaluated in a randomized manner by a single investigator (K. M.)
who was blinded to the treatment conditions. Data are presented as means ± SE
and were analyzed by Student’s t-test or by analysis of variance with a Bonferroni
correction for multiple group comparisons.
3.3 Results
Low concentrations of IL-1β induce β-cell proliferation, are
anti-apoptotic and enhance β-cell secretory function.
Human islets were cultured on extracellular matrix-coated plates in the presence of
increasing IL-1β concentrations for 4 days. Exposure to 0.02 ng/ml IL-1β induced a
2-fold increase in β-cell proliferation compared to controls, but exposure to higher
concentrations of 2 and 5 ng/ml resulted in an approximately 1.5-fold decrease (Fig-
ure 3.1 A & B). By contrast, 0.01 ng/ml IL-1β reduced baseline β-cell apoptosis 2-
fold whereas higher doses of 2 and 5 ng/ml IL-1β increased the apoptosis rate by 2.3-
and 3.6-fold, respectively (Figure 3.1 A & C). These changes in β-cell turnover were
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accompanied by a 1.6-fold increase in glucose stimulated insulin secretion (GSIS)
at 0.02 ng/ml IL-1β and a 2.8-fold reduction by 2 ng/ml IL-1β (Figure 3.1 D & E).
Insulin content of the islets was not significantly affected.
Endo- and exogenous modulation of IL-1β signaling by IL-1Ra.
We have recently shown expression of IL-1Ra in human β-cells [39]. Interestingly
secreted IL-1Ra will antagonise the effect of IL-1β. To highlight the potential cross
talk between these two molecules, we repressed endogenous production of IL-1Ra by
RNA interference. As previously shown, small interfering RNA directed to IL-1Ra
(siIL-1Ra) with a transfection efficiency of 70% suppressed IL-1Ra mRNA by 69 ±
6% [39]. Blockade of endogenous IL-1Ra by siIL-1Ra did not significantly affect
baseline β-cell proliferation (Figure 3.2 A) but led to a 2-fold increase in apoptosis,
levels similar to the ones obtained with 2 ng/ml of IL-1β (Figure 3.2 B). Addition
of 0.02 ng/ml IL-1β failed to increase β-cell proliferation and to further increase
β-cell apoptosis (Figure 3.2 A & B). In contrast, addition of exogenous rhIL-1Ra
(500 ng/ml) increased β-cell proliferation and protected from the deleterious effects
of a high concentration, 2 ng/ml, of IL-1β. Furthermore, the compound protected
cells against prolonged exposure to 33.3 mM glucose (Figure 3.2 A & B). Similarly,
siIL-1Ra completely blocked GSIS in the absence or presence of 0.02 ng/ml IL-
1β, whereas exogenous rhIL-1Ra prevented the impairment of GSIS in the presence
of 2 ng/ml IL-1β or 33.3 mM glucose (Figure 3.2 C & D). Interestingly, the low
concentration of 0.02 ng/ml IL-1β induced a 1.8-fold increase in the release of its
receptor antagonist IL-1Ra into the culture medium (Figure 3.2 E).
Low dose interleukin-1β-induced β-cell proliferation is mediated via
the Fas-FLIP pathway and may involve PDX-1 and Pax4.
Next we investigated the underlying mechanisms of the proliferative effect of IL-1β.
We hypothesized that the Fas pathway mediates IL-1β induced β-cell proliferation.
To test this hypothesis, first we investigated whether low concentrations of IL-1β are
capable of inducing Fas. Exposure of human islets to 0.02 ng/ml IL-1β for 4 days
induced Fas expression to levels similar to those observed with higher concentrations
of IL-1β and 33.3 mM glucose (Figure 3.3 A). However, low concentrations of IL-1β
did not activate caspase-8, the most upstream caspase in the Fas apoptotic pathway,
while higher concentrations than 0.02 ng/ml IL-1β caused cleavage of procaspase-
8, releasing the active form of the protease (Figure 3.3 B). To examine whether the
induction of proliferation by 0.02 ng/ml of IL-1β is caused by interaction of con-
stitutively expressed FasL [16, 28] and up-regulated Fas, we used the Fas antago-
nistic antibody ZB4. ZB4 inhibited the proliferative effect of IL-1β (Figure 3.3C).
Since Fas signaling may induce proliferation in the presence of FLIP [34], we an-
alyzed FLIP protein modulation by increasing concentrations of IL-1β. Similar to
IL-1β-mediated changes in β-cell proliferation (Figure 3.1 B), low concentrations of
IL-1β induced FLIP expression, while higher concentrations were inhibitory (Fig-
ure 3.3 D & E). Of note, FLIP mRNA expression remained unchanged in agreement
with previous studies showing regulation of FLIP only at protein level [34]. The
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Figure 3.1: Low concentrations of IL-1β induce β-cell proliferation, are anti-apoptotic
and enhance β-cell secretory function: Human islets were cultured on extracellular matrix-
coated dishes for 4 days at 5.5 mM glucose with increasing concentrations of IL-1β. Double
immuno-staining for β-cell proliferation with anti-Ki-67 in brown (A 1–3) and anti-insulin
in green (A 4–6) and for β-cell apoptosis with the TUNEL assay in black and anti-insulin
in brown (A 7–9), in control islets (A 1, 4, 7) and in islets treated with 0.02 ng/ml (A 2,
5, 8) and with 2 ng/ml (A 3, 6, 9) IL-1β. The orange arrows mark β-cells stained positive
for Ki-67 and insulin, and the black arrow marks a TUNEL positive β-cell. Percentage of
Ki-67-positive (B) and TUNEL-positive (C) β-cells normalized to control incubations at
5.5 mM glucose alone (100%; in absolute values: 0.19 ± 0.07% Ki-67-positive β-cells and
0.40 ± 0.05% TUNEL-positive β-cells). The mean number of islets scored was 41 (B) and
52 (C) for each treatment condition from each donor. Basal and glucose-stimulated insulin
secretion denote the amount secreted during successive 1-hour incubations at 2.8 mM (basal)
and 16.7 mM (stimulated) glucose following the 4-day culture period expressed as secreted
insulin (D) or stimulatory index (E). Islets were isolated from four organ donors. Results are
means ± SE. * p < 0.05 to untreated controls.
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Figure 3.2: Endo- and exogenous modulation of IL-1β signaling by IL-1Ra: Human islets
were cultured on extracellular matrix-coated dishes for 4 days at 5.5 or 33.3 mM glucose
alone or with increasing concentrations of IL-1β or after transfection with 50 nM siIL-1Ra
or with addition of 500 ng/ml exogenous recombinant human IL-1Ra. Results are means ±
SE of percentage of Ki-67-positive (A) and TUNEL-positive (B) cells. The mean number
of islets scored was 45 (A) and 43 (B) for each treatment condition from each donor. Basal
and glucose-stimulated insulin secretion denote the amount secreted during successive 1-
hour incubations at 2.8 mM (basal) and 16.7 mM (stimulated) glucose following the 4-day
culture period expressed as secreted insulin (C) or stimulatory index (D). (E) Secretion of
IL-1Ra from human islets during 4 days of culture. Data were collected from three tubes per
treatment in five separate experiments from five donors. Results are means ± SE. * p < 0.05
to untreated control. ** p < 0.05 to 0.02 ng/ml IL-1β alone. + p < 0.05 to 2 ng/ml IL-1β
alone. # p < 0.05 to 33 mM glucose alone.
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functional role of FLIP in IL-1β-induced β-cell proliferation was then investigated
by RNA interference (siFLIP). siFLIP suppressed FLIP expression in most β-cells
(Figure 3.3 F) leading to a 5.2-fold decrease in FLIP protein expression (for rep-
resentative blot, see Figure 3G). Repression of FLIP resulted in impaired baseline
β-cell proliferation and prevented IL-1β mediated replication, whereas scrambled
siRNA had no effect on the number of Ki-67 positive β-cells (Figure 3.3 H). We
next investigated the potential implication of the transcription factors PDX-1 and
Pax4, known to promote β-cell replication [40–45]. Low concentrations of IL-1β
stimulated PDX-1 mRNA and protein expression which were decreased by higher
concentrations of IL-1β (Figure 3.3 I–K). Similarly, low concentrations of IL-1β
stimulated Pax4 and insulin mRNA expression, which was decreased by higher con-
centrations (Figure 3.3 L & M). However, the stimulation of insulin mRNA by low
IL-1β failed to reach statistical significance. Furthermore, Pax4 was stimulated at 12
hours but no longer after 4 days.
Impaired glucose tolerance in IL-1β knockout mice.
To substantiate the role of IL-1β in normal glucose homeostasis in vivo, glucose
tolerance tests were performed on IL-1β knockout (ILKO) mice. As predicted, we
found that ILKO mice displayed glucose intolerance (Figure 3.4 A). Normal sensi-
tivity of the ILKO mice to injected insulin (Figure 3.4 B) ruled out the possibility
that insulin resistance was responsible for the impaired glucose tolerance. Food in-
take and body weight were similar in ILKO and WT mice (not shown). Analysis
of pancreatic tissue of ILKO mice revealed a normal structure of the islets with no
significant decrease in β-cell mass (Figure 3.4 C & D). However, insulin mRNA
expression was strongly decreased (Figure 3.4 E) although pancreatic insulin con-
tent showed no significant changes (5.05 ± 1.04 versus 4.0 ± 0.7 mol/g insulin per
pancreas in normal versus ILKO mice, respectively). Consistent with our in vitro ex-
periments, Fas, FLIP, PDX-1 and Pax4 were decreased in ILKO mice (Figure 3.4 E).
Islets of ILKO mice exhibited a strong decrease in baseline β-cell proliferation and
GSIS compared to WT mice, while apoptosis and insulin content were not signifi-
cantly different (Figure 3.5). The resistance of ILKO islets to β-cell glucotoxicity
was then studied. Chronic exposure of wildtype mouse islets to 33.3 mM glucose
for 4 days impaired β-cell proliferation, induced apoptosis, impaired GSIS and de-
creased insulin content (Figure 3.5). In contrast, islets of ILKO mice were not further
altered by high glucose concentrations (Figure 3.5), supporting the concept of IL-1β
mediated glucotoxicity [18]. Finally, we have confirmed that glucose regulates IL-1β
secretion in mouse islets (2.85± 0.8 and 5.68± 1.6 pg/ml of IL-1β in islets cultured
for 4 days in 11.1 and 33.3 mM glucose, respectively, n = 5) as described in human
islets [18].
3.4 Discussion
The role of IL-1β and other cytokines in the pathogenesis of type 1 diabetes is well
established [25, 46]. More recently the concept emerged that cytokines may also me-
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Figure 3.3: Low dose IL-1β-induced β-cell proliferation is mediated via the Fas-FLIP
pathway and involves PDX-1 and Pax4: Human islets were cultured on extracellular ma-
trix coated dishes and exposed for 4 days to increasing IL-1β concentrations or 33.3 mM
glucose or 500 ng/ml of the antagonistic anti-Fas antibody ZB4 or 50 nM siRNA to FLIPL
(siFLIPL) or to scrambled siRNA (siScr). (A) Quantitative RT-PCR analysis of Fas expres-
sion. (B) Representative immunoblotting of caspase 8 and actin. For detection of caspase-8,
an antibody recognizing full length (procaspase-8; 55 kDa), and the 14 kDa processed active
form of caspase-8 was used. (C) β-cell proliferation determined by double staining with
anti-Ki-67 and anti-insulin. (D) Representative immunobloting of FLIPL and actin. (E) The
density of expression levels was quantified after scanning, and normalised to actin levels. (F)
Double immunostaining of the islets with anti-FLIPL (1,3) and anti-insulin (2,4) antibodies
in control islets (1,2) and siFLIPL treated islets (3,4). (G) Representative immunobloting of
FLIPL and actin. (H) β-cell proliferation determined by double staining with anti-Ki-67 and
anti-insulin. (I) Quantitative RT-PCR analysis of PDX-1 expression. (J) Representative im-
munoblotting of PDX-1 and actin. (K) The density of expression levels were quantified after
scanning and normalised to actin levels. (L) Quantitative RT-PCR analysis of Pax4 in islets
exposed for 12 h to IL-1β and (M) of insulin in islets exposed for 4 days to IL-1β. Results
are means ± SE. In the LightCycler quantitative PCR system, the levels of Pax4 and insulin
expression were normalized against tubulin or cyclophylin and the results were expressed
as mRNA levels relative to control incubations. The antibodies were blotted on the same
membrane after stripping, actin was used as loading control. Islets were isolated from six
organ donors. * p < 0.05 to untreated controls, ** p < 0.05 to 0.02 ng/ml IL-1β.
diate nutrient induced β-cell dysfunction during the development of type 2 diabetes
[5, 6, 47, 48]. Intriguingly, some of these cytokines can be produced by β-cells,
including IL-6, IL-1β, IL-1Ra, and PANDER [18, 19, 39, 49–53]. The fact that the
non-immune β-cell synthesizes cytokines suggests their implication in islet physiol-
ogy. Accordingly, we observed beneficial effects of low concentrations of IL-1β on
β-cell proliferation, apoptosis and secretory function.
A low concentration of IL-1β stimulated IL-1Ra which in turn stimulated β-cell
proliferation. Likewise, adenoviral expression of IL-1Ra increases β-cell replica-
tion in rat islets [54]. At first sight, these results suggest a signalling function for
IL-1Ra. However, this is unlikely since IL-1Ra only has a single IL-1 receptor bind-
ing domain and is therefore unable to recruit the IL-1 receptor accessory protein,
the second chain of the receptor complex, which is believed to be necessary for sig-
nalling [55]. Therefore the proliferative effects of exogenous IL-1Ra probably result
from a restoration of a beneficial ratio of IL-1 to IL-1Ra, and not from direct effects
of the latter. Corroborating this hypothesis, repression of endogenous IL-1Ra was
deleterious, probably due to unbalanced actions of IL-1.
Fas expression on the surface of pancreaticβ-cells contributes to cytokine-induced
apoptosis [30, 56]. However, when FLIP is activated, Fas becomes mitogenic [34].
We propose that the Fas-FLIP pathway is modulated by IL-1β. This is supported
by a simultaneous elevation of Fas and FLIP proteins at low IL-1β concentrations
leading to β-cell proliferation. In contrast, higher concentrations of IL-1β decreased
FLIP while Fas remained elevated leading to decreased proliferation and induction
of apoptosis. Furthermore, the Fas antagonistic antibody ZB4 and siRNA to FLIP,
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Figure 3.4: Impaired glucose tolerance in IL-1β knockout mice: Blood glucose levels fol-
lowing i.p. injection of glucose (A) or insulin (B) in 3 month old male IL-1β knockout
(ILKO) and wildtype (WT) C57BL/6j mice. * indicates p < 0.05, ILKO versus WT. Data
were collected from three separate experiments, each with five animals per group. (C) Dou-
ble immunostaining for glucagon in red (1, 3) and insulin in green (2, 4) and (D) β-cell mass
in tissue sections of 4 month old male WT (1, 2) and ILKO mice (3, 4); n = 5 for each group.
(E) Quantitative RT-PCR detection of insulin, PDX-1, Pax4, FLIP and Fas mRNA expres-
sion. Total RNA was isolated from ILKO and WT islets after 1 day in culture. The level
of mRNA expression was normalized to GAPDH and the results expressed as percentage of
WT islet mRNA levels; n = 3 for each group of mice islets, each in duplicate. * p < 0.05 to
WT islets.
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Figure 3.5: Resistance of IL-1β−/− islets to glucotoxicity: Isolated islets from male IL-
1β knockout (ILKO) and wildtype (WT) mice were cultured on extracellular matrix-coated
dishes for 4 days at 11.1 mM or 33.3 mM glucose. Results are means ± SE of percentage
of Ki-67-positive (A) and TUNEL-positive (B) β-cells. The mean number of islets scored
was 132 (A) and 118 (B) for each treatment condition in three independent experiments. (C)
Basal and glucose-stimulated insulin secretion denote the amount secreted during successive
1-hour incubations at 2.8 mM (basal) and 16.7 mM (stimulated) glucose following the 4-day
culture period expressed as secreted insulin (C) or stimulatory index (D). (E) insulin content.
Results are means± SE. Islets were isolated from nine mice for each treatment group in three
independent experiments. * p < 0.05 to WT mice.
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both prevented IL-1β induced β-cell proliferation.
The physiological importance of IL-1β was also apparent in IL-1β knockout mice,
which showed impaired glucose tolerance. Islets of these mice displayed decreased
mRNA expression levels of PDX-1, Pax4, insulin, Fas and FLIP. Of note, these
transcripts were enhanced by 0.02 ng/ml IL-1β. At higher concentrations, IL-1β
suppressed these factors uncovering its toxic effects. IL-1β may participate in gluco-
toxicity [18], a concept substantiated by the protection from harmful actions of high
glucose of IL-1β knockout mouse islets.
Most factors playing a role in β-cell turnover are also involved in the regulation of
β-cell secretory function [57]. This is also true for IL-1β, which has distinct effects
depending on the duration of exposure. On the short-term, IL-1β predominantly
influenced β-cell secretory function independently of changes in β-cell mass. In-
deed, in vitro, a 4-day exposure of human islets to different concentrations of IL-1β
led to changes in cell turnover in less than 1% of β-cells although β-cell secretory
function was almost completely blocked at high concentrations. Nevertheless, this
does not mean that prolonged exposure to IL-1β will not affect β-cell mass. Indeed,
β-cells remain positive for Ki-67 for approximately 12 hours. In absolute value,
0.02 ng/ml IL-1β increased the number of proliferating β-cells by 0.2%. The human
pancreas has between 500,000 to 1,000,000 islets, comprising 500 to 2,000 β-cells
each. Therefore, it can be estimated that low concentrations of IL-1β will increase
the number of β-cells by approximately 4,000,000 per day, leading to a doubling of
β-cell mass within 250 days. Such an impressive increase in β-cell mass may occur
in vivo over a similar time period (e.g. during obesity [4]). Therefore, the observed
differences are within an expected range and support the relevance of the finding.
A key signaling molecule regulating β-cell turnover and function is IRS-2 [58].
Interestingly, it has been proposed that IL-1β may mediate its deleterious effects via
IRS-2 degradation [8]. Conversely, it is conceivable that at low concentrations IL-1β
also signals via IRS-2. Indeed, while IRS-2 degradation leads to apoptosis, IRS-2 ac-
tivation enhances β-cell proliferation and function. However, further investigations
are required to support this hypothesis.
Cytokines are central in the development of diabetes. However, at low concen-
trations, IL-1β promotes β-cell function and survival. Therefore, glucose-induced
IL-1β may have an important role in the long-term adaptation of the β-cells to hy-
perglycemia. Short term exposure to hyperglycemia will induce low levels of IL-1β,
inducing IL-1Ra, Fas and FLIP, leading to decreased apoptosis and enhanced prolif-
eration and function. However, prolonged hyperglycemia will increase the ratio of
IL-1β to IL-1Ra decreasing FLIP and directing Fas to signals deleterious to the cell.
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Abstract
Type 2 diabetes is characterized by a deficit in β-cell mass and its incidence
increases with age. Here we analyzed β-cell turnover in islets from 2–3 com-
pared to 7–8 month old rats and in human islets from 53 organ donors with
ages ranging from 17 to 74 years. In cultured islets from 2–3-month old rats,
the age at which rats are usually investigated, increasing glucose from 5.5 to
11.1 mM decreased β-cell apoptosis, which was augmented when glucose was
further increased to 33.3 mM. In parallel, β-cell proliferation was increased by
both 11.1 and 33.3 mM glucose compared to 5.5 mM. In contrast, in islets from
7–8 month old rats and from adult humans, increasing glucose concentrations
from 5.5 to 33.3 mM induced a linear increase in β-cell death and a decrease in
proliferation. Additionally, in cultivated human islets, age correlated positively
with the sensitivity to glucose-induced β-cell apoptosis and negatively to base-
line proliferation. In rat islets, constitutive expression of Fas-ligand (FasL) and
glucose-induced Fas receptor expression were observed only in 7–8 month but
not in 2–3 month old islets. Moreover, PDX-1 expression decreased with age
in pancreatic tissue sections of rats and humans. Furthermore, older rat islets
were more sensitive to the high glucose mediated decrease in PDX-1 expression
than younger islets. Therefore, differences in glucose sensitivity between hu-
man and 2–3 month old rat islets may be due to age-dependent changes rather
than to genetic background. These data provide a possible explanation for the
increased incidence of type 2 diabetes at an older age and support the use of
islets from older rats as a more appropriate model to study glucose-induced
β-cell apoptosis.
4.1 Introduction
The prevalence of type 2 diabetes increases with age due to alteration or insufficient
compensation of β-cell functional mass in the face of increasing insulin resistance
[1–4]. While the existence of an inadequate adaptation of β-cell mass in patients
with type 2 diabetes is beyond controversy [5–9], the effect of age on the sensitivity
to pro-apoptotic stimuli of the human β-cell remains to be investigated.
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Changes in glucose concentrations are key regulators of β-cell proliferation and
apoptosis. Indeed, graded increases in glucose concentrations induce β-cell apopto-
sis in cultured islets from the diabetes-prone Psammomys obesus and from human
islets [10–13]. In contrast, in islets from 2–3-month old rats, the age at which rats
are usually investigated, an increase in glucose concentrations to 11.1 mM promotes
β-cell survival [10, 14]. When glucose concentrations are further increased, glucose
proves to be pro- or anti-apoptotic depending on culture conditions [10, 14, 15].
Investigations of β-cell proliferation revealed induction of proliferation by glucose
in rat, Psammomys obesus and human islets [10, 11, 16]. Nevertheless, unlike the
long-lasting effect in rat islets, only a transient and reduced proliferative response
was observed in Psammomys obesus and human islets. Previous studies have shown
that β-cell replication declines as rodents age and stabilizes at a rate of 1–3% per
day [17–19] or even lower according to recent data [20]. However, β-cell turnover
in aging humans remains unclear.
In human islets, the mechanism underlying glucose-induced β-cell apoptosis and
impaired proliferation, involves the up-regulation of the Fas receptor, which interacts
with the constitutively expressed Fas-ligand (FasL) on neighboring β-cells [11, 21].
In an interesting study, J. Hanke detected expression of FasL in β-cells of 6 month
and older rats while FasL was not expressed in younger animals [22]. It is not known
whether glucose-induced Fas is age-dependent.
Pancreatic duodenal homeobox-1 (PDX-1) is a β-cell specific transcription factor
regulating β-cell differentiation and secretory function [23]. Furthermore, PDX-1
promotes β-cell replication and is cytoprotective [24–26]. Interestingly, in human
pancreatic islets, PDX-1 may mediate deleterious effects of high glucose concentra-
tions [27].
Therefore, we investigated the changes in β-cell turnover in relation to age. We
show that age correlates with decreased proliferative activity and enhanced sensi-
tivity to glucose-induced apoptosis. In parallel, constitutive expression of FasL and
inducible Fas expression appeared along with decreased expression of PDX-1 under
normal and gluco-toxic conditions.
4.2 Research design and methods
4.2.1 Islet isolation and culture
Human islets were isolated from pancreata of 53 organ donors. Islet purity was
greater than 95% as judged by dithizone staining (if this degree of purity was not
achieved by routine isolation, islets were hand-picked). The donors, aged 17–74
years, were heart-beating cadaver organ donors, and none had a previous history
of diabetes or metabolic disorders. Male Sprague Dawley rats, aged 2–3 months
(200–220 g) and 7–8 months (500–600 g), were anesthetized and islets isolated from
the pancreata as previously described [28]. The islets were cultured on extracel-
lular matrix-coated plates derived from bovine corneal endothelial cells (Novamed
Ltd., Jerusalem, Israel), allowing the cells to attach to the dishes and spread. This
mono- or bi-layer of cells has direct access to nutrients and oxygen allowing long-
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term preservation of their functional integrity. Human islets were cultured in CMRL
1066 medium containing 5.5 mM glucose and rat islets were cultured in RPMI 1640
medium containing 11.1 mM glucose, both supplemented with 100 U/ml penicillin,
100 µg/ml streptomycin and 10% FCS (Invitrogen Ltd., Carlsbad, CA), hereafter re-
ferred to as culture medium. Two days after plating, when most islets were attached
and had begun to flatten, the medium was changed to culture medium containing 5.5,
11.1 or 33.3 mM glucose for four days.
4.2.2 Detection of Fas, FasL and PDX-1 expressing β-cells
Pancreata from routine necropsies were immersion-fixed in formalin followed by
paraffin embedding. Sections were deparaffinized and rehydrated and endogenous
peroxidase blocked by submersion in 0.3% H2O2 for 15 min., after that, sections
were incubated in methanol for 5 min and double stained with rabbit anti-PDX-1
antibody (kindly provided by Christopher Wright, Vanderbilt University Medical
Center, Nashville) and insulin. Islet cultures were fixed in 4% paraformaldehyde
(30 min, room temperature) followed by permeabilisation with 0.5% triton X-100 (4
min, room temperature) and were double-labeled for Fas receptor, FasL or PDX-1
by 1 h exposure to 10% bovine serum albumin, followed by incubation with rabbit
anti-Fas (FL-335, Santa Cruz Biotech, Santa Cruz, CA), mouse anti-FasL (Trans-
duction Laboratories, Lexington, KY), and detection using the streptavidin-biotin-
peroxidase complex (Zymed, San Francisco, CA) or donkey anti-mouse Cy3 con-
jugated antibody (Jackson, Immunoresearch Laboratories, West Grove, PA). Sub-
sequently, the specimens were stained for insulin as previously described [10, 11].
The specificity of the Fas and FasL antibodies was assessed previously [11]. Satura-
tion of staining was analyzed using analySISTM 3.1 software (Soft Imaging System
GmbH, Muenster, Germany).
4.2.3 Beta-cell replication and apoptosis
For β-cell replication and apoptosis studies, islet cells were double stained with ei-
ther a monoclonal antibody against the human or rat Ki-67 antigen (Zymed) or by
terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)
according to the manufacturer’s instructions (In Situ Cell Death Detection Kit, AP;
Boehringer Mannheim, Germany) and for insulin as described above.
4.2.4 Western blot analysis
Islets were cultured in suspension in RPMI 1640 (rat) or CMRL 1066 (human)
medium as described above. Equivalent amounts of protein from each treatment
group were run on 15% SDS polyacrylamide gels as described previously [29]. Pro-
teins were electrically transferred to nitrocellulose filters and incubated with rabbit
anti-Fas antibody (FL-335, Santa Cruz Biotech, Santa Cruz, CA), mouse anti-FasL
(Transduction Laboratories), or with mouse anti-PDX-1 (kindly provided by Ste-
fan Zahn, Novo Nordisk A/S, Bagsvrd, Denmark) or rabbit anti-actin (Cell signal-
ing Technology, MA, USA) antibodies followed by incubation with horseradish-
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peroxidase-linked anti-rabbit or anti-mouse IgG (Santa Cruz Biotechnology Inc.).
Immune complexes were detected by chemiluminescence using LumiGLO (Cell Sig-
nalling).
4.2.5 RNA extraction and quantitative RT-PCR
Total RNA was extracted from the cultured islets by using the RNeasy mini kit (Qi-
agen Inc., Basel, Switzerland) and RT-PCR was performed using the SuperScript
Double-Stranded cDNA synthesis kit according to the manufacturer’s instructions
(Life Technologies, Gibco, Gaithersburg, MD). For quantitative analysis, we used
the LightCycler quantitative PCR system (Roche, Basel, Switzerland) with a com-
mercial kit (Light Cycler-DNA Master SYBR Green I; Roche). The primers were
5′CCACCTTGGGACCTGTTTAG3′ and 5′TGATGCCAGAGGAAGAGGAG3′ (hu-
man PDX-1); 5′GAGGACCCGTACAGCCTACA3′ and 5′CGTTGTCCCGCTAC-
TACGTT3′ (rat PDX-1); 5′TTCTTCTACACACCCA3′ and 5′CTAGTTGCAGTA-
GTTCT3′ (insulin) 5′AGAGTCGCGCTGTAAGAAGC3′ and 5′TGGTCTTGTCA-
CTTGGCATC3′ (α-Tubulin); 5′AACAGCGACACCCACTCCTC3′ and 5′GGAG-
GGGAGATTCAGTGTGGT3′ (GAPDH).
4.2.6 Glucose stimulated insulin secretion
For acute insulin release in response to glucose, islets were washed and pre-incubated
(30 min) in Kreb’s Ringer bicarbonate buffer (KRB) containing 2.8 mM glucose and
0.5% BSA. KRB was then replaced by KRB 2.8 mM glucose for 1 h (basal), fol-
lowed by an additional 1 h in KRB 16.7 mM glucose. Islets were extracted with 0.18
N HCl in 70% ethanol for determination of insulin content. Insulin was determined
using a human insulin RIA kit (CIS bio international, Gif-Sur-Yvette, France), which
has similar affinity for both rat and human insulin.
4.2.7 Evaluation and statistical analysis
Samples were evaluated in a randomised manner by a single investigator (K. M.)
blind to the treatment conditions. Data were analysed by Student’s t-test, or by
analysis of variance with a Bonferroni correction for multiple group comparisons, or
by regression analysis using GraphPad Prism, version 3.0 (San Diego, CA, USA).
4.3 Results
4.3.1 Distinct effects of glucose-induced changes in β-cell
apoptosis and proliferation are not species- but
age-dependent
Analysis of human islets cultured for 4 days at 11.1 and 33.3 mM glucose revealed
a 2.0- and 2.8-fold increase in β-cell nuclei with DNA fragmentation (TUNEL-
positive, Fig. 4.1 A), respectively, relative to islets at 5.5 mM glucose. In parallel,
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β-cell proliferation was 1.5-fold and 2.7-fold reduced by 11.1 and 33.3 mM glu-
cose, respectively (Fig. 4.1 B). In contrast, exposure of 2–3 month old rat islets to
increasing glucose concentrations resulted in an inverse bell-shaped response. The
lowest incidence of apoptotic β-cell nuclei occurred at a glucose concentration of
11.1 mM and increased 3.6- and 3.0-fold at 5.5 mM and 33.3 mM glucose, respec-
tively (Fig. 4.1 C & G). Proliferation of 2–3 month old rat β-cells was increased by
1.9- and 1.8-fold at 11.1 and 33.3 mM glucose, respectively, as compared to islets at
5.5 mM glucose (Fig. 4.1 D & G). However, islets from 7–8 month old rats behaved
similarly to human islets, with a progressive induction of β-cell apoptosis of 1.3- and
2.9-fold by 11.1 mM and 33.3 mM glucose , respectively, and a 1.4-fold decrease of
β-cell proliferation at 33.3 mM glucose (Fig. 4.1 E–G).
4.3.2 Aging correlates with enhanced sensitivity to
glucose-induced β-cell apoptosis and decreased
baseline proliferation
Since the incidence of diabetes increases with age, we were interested to know
whether this correlates with changes in the proliferative capacity and in the sen-
sitivity to glucose-induced apoptosis of β-cells. Therefore we analyzed baseline
and glucose-stimulated apoptosis and proliferation rates of β-cells from cultivated
islets from 53 organ donors with ages ranging from 17 to 74 years. Mean baseline
β-cell apoptosis at 5.5 mM glucose after four days of culture was 0.43% TUNEL
positive β-cells and did not significantly change with age (Fig. 4.2 A). However,
there was a significant correlation between the age of the donor and the sensitiv-
ity to glucose-induced apoptosis (Fig. 4.2 B). In contrast, the baseline proliferation
rate of cultured human β-cells was negatively correlated with increasing age of the
donor whereas the deleterious effect of glucose on the replicating rate of β-cells was
age-independent (Fig. 4.2 C & D).
4.3.3 Age-dependent appearance of the Fas/FasL system
In human islets, the mechanism underlying glucose-inducedβ-cell apoptosis and im-
paired proliferation involves the up-regulation of Fas, which interacts with constitu-
tively expressed FasL on neighboring β-cells [11]. Therefore, we hypothesized that
age-dependent changes in Fas and FasL expression could explain differences in β-
cellapoptosis and proliferation seen in rats of different ages. Double-immunostaining
of cultivated islets from 2–3 month old rats revealed neither expression of the Fas re-
ceptor nor of FasL at 5.5 mM and 33.3 mM glucose (Fig. 4.3 A, panels 1–8). In
contrast, β-cells from 7–8 month old rats constitutively expressed FasL at low and
high glucose concentrations (Fig. 3 A, panels 9–12). Moreover, similar to human
β-cells [11], glucose induced expression of Fas at 11.1 mM and 33.3 mM glucose
concentrations (Fig. 4.3 A, panels 15 & 16), compared to 5.5 mM (Fig. 4.3 A, pan-
els 13 & 14). Age-dependent Fas receptor and FasL expression was confirmed by
Western Blot analysis of lysates from 2–3 and 7–8 month old rat islets cultured in
suspension at 5.5, 11.1 and 33.3 mM glucose (Fig. 4.3 B). After 30 and 96 h of cul-
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Figure 4.1: Response to glucose-induced changes in β-cell apoptosis and proliferation are
age-dependent. Human (A, B), 2–3 month (C, D & G panels 1–4 & 9–12) and 7–8 month
old rat (E, F & G panels 5–8 & 13–16) pancreatic islets were cultured on extracellular
matrix-coated dishes, exposed for 4 days to media containing 5.5, 11.1 or 33.3 mM glucose
and double-immunostained for insulin and DNA fragmentation by the TUNEL assay (A, C,
E & G panels 1–8) or for proliferation by the Ki-67 antibody (B, D, F & G panels 9–16).
Results are means ± SE of the relative percentage of TUNEL-positive or Ki-67-positive β-
cells relative to control incubations at 5.5 mM glucose alone (100%; in absolute values: A:
0.43% TUNEL positive β-cells, B: 0.53% Ki67-positive β-cells, C: 0.82% TUNEL positive
β-cells, D: 2.06% Ki67-positive β-cells, E: 1.10% TUNEL positive β-cells and F: 0.83%
Ki67-positive β-cells at 5.5 mM glucose alone). The mean number of islets scored was A:
81, B: 74, C: 65, D: 55, E: 71, F: 76 for each treatment condition from each donor. Islets
were isolated from seven human organ donors and from 32 rats aged 2–3 and 7–8 months.
* p < 0.05 relative to islets at 5.5 mM glucose, ** p < 0.05 relative to islets at 11.1 mM
glucose.
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Figure 4.2: Aging correlates with enhanced sensitivity to glucose-induced β-cell apoptosis
and decreased baseline proliferation. Human pancreatic islets were isolated from 53 or-
gan donors of ages ranging from 17 to 74 years and cultured on extracellular matrix-coated
dishes, exposed for four days to media containing 5.5 or 33.3 mM glucose and double-
immunostained for insulin and the TUNEL assay (A & B) or the Ki-67 antibody (C & D).
Correlation between age and means of the percentage of TUNEL-positive or Ki-67-positive
β-cells at baseline 5.5 mM glucose (A & C) or at 33.3 mM glucose relative to control incu-
bations at 5.5 mM glucose alone. Each datum point represents an independent experiment
of one organ donor. Solid lines are best fit, with broken lines showing 95% Cis.
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ture, FasL was present in the 7–8 month old rats at all glucose concentrations, but not
in the 2–3 month old rats. Fas receptor was up-regulated in the 7–8 month old rats by
11.1 and 33.3 compared to 5.5 mM glucose after 30 h, and at higher levels after 96 h
of culture. Finally, Fas receptor was almost undetectable in the islets of 2–3 month
old rats cultured at low or high glucose concentrations for 30 or 96 h. In contrast, in
human islets, FasL was already present at 5 days of age, and no changes in expres-
sion levels could be detected with aging (Fig. 4.3 C). We also performed analysis for
the Fas receptor in humans at different ages from 21 to 71 years. Increasing glucose
concentrations induced Fas receptor up-regulation, but no age dependent differences
could be quantified (Fig. 4.3 D). In parallel, β-cell secretory function was analyzed.
Glucose stimulated insulin secretion decreased with age in rats as well as in humans
(Fig. 4.3 E).
4.3.4 Beta-cell expression of PDX-1 decreases with age
We next studied the influence of aging on PDX-1 expression under normal and glu-
cotoxic conditions. Beta-cell expression of PDX-1 was strongly decreased in islets
of 7–8 month old rats as compared to younger rats. This was observed by West-
ern Blotting of cultured islet lysates (Fig. 4.4 A), quantitative RT-PCR (Fig. 4.4 B)
and by immunostaining of tissue sections (Fig. 4.4 C & D). Exposure of the islets
to increasing glucose concentrations for 30 and 96 h decreased PDX-1 expression
in 7–8 month old islets whereas in 2–3 month old islets a decrease occurred only
after prolonged culture for 96 h but not after 30 h (Fig. 4.4 A). Subsequently we
analyzed tissue sections from necropsies of 18 human pancreata from non-diabetic
individuals from 5 days to 79 years old. PDX-1 was clearly expressed in β-cells of
young individuals whereas it was barely detectable in pancreata of old individuals
(for representative images see Fig. 4.4 E). Quantitative analysis of the intensity of
the PDX-1 staining revealed a significant negative correlation between the age of the
patients and PDX-1 expression (Fig. 4.4 F). Finally, PDX-1 mRNA expression levels
from 23 human islet isolations were studied and also revealed a negative correlation
with age, both compared to tubulin (Fig. 4.4 G) or GAPDH.
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Figure 4.3: Age-dependent appearance of the Fas/FasL system. Pancreatic islets isolated
from 2 month (A panels 1–8 & B) and 8 month (A panels 9–16 & B) old rats, and from
21 year (C panels 1–8 & D) and 71 year old humans (C panels 9–16 & D) were cultured
on extracellular matrix coated dishes (A & C) or in suspension (B & D), and exposed for
30–96 h to media containing 5.5, 11.1 or 33.3 mM glucose. Double-immunostaining for
insulin in green (A & C odd-numbered panels) and FasL (A & C panels 2, 4, 10, 12)
or the Fas receptor in red (A & C panels 6, 8, 14, 16). (B & D): Western Blot analysis
of FasL, Fas and actin. The antibodies were blotted on the same membrane after stripping.
One representative of three experiments from isolated islets from 2–3 and 7–8 month old
rats and from 18–21 and 60–71 year old human organ donors is shown, respectively. (E) In
parallel, β-cell secretion assays from the isolated rat and human islets were performed. Basal
and glucose-stimulated insulin secretion denote the amount secreted during successive 1-
hour incubations at 2.8 mM (basal) and 16.7 mM (stimulated) glucose, normalised to insulin
content and expressed as percent change from basal secretion. Islets were isolated from
four 2–3 month old and four 7–8 month old rats, and from four 18–24 year old and four
60–71 year old human organ donors and plated in four dishes per experiment. * p < 0.05
relative to stimulated insulin secretion from 2–3 month old rats and 18–24 year old humans,
respectively.
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Figure 4.4: Beta-cell expression of PDX-1 decreases with age. (A) Pancreatic islets isolated
from 2–3 and 7–8 month old rats were cultured in suspension and exposed for 30 or 96 h to
media containing 5.5, 11.1 or 33.3 mM glucose. Western Blot analysis of PDX-1 and actin.
The antibodies were blotted on the same membrane after stripping. One of three experiments
is shown. (B) RT-PCR quantification of PDX-1 mRNA expression in total RNA isolated from
2 and 8 month old rat islets following overnight incubation at 11.1 mM glucose. The levels
of PDX-1 expression were normalized against tubulin. Double-immunostaining for PDX-1
in red (C panels 2, 4 & E even-numbered panels) and insulin in green (C panels 1, 3 &
E odd-numbered panels) on pancreatic sections from 2–3 and 7–8 month old rats (C & D)
and from 5 days, 5, 13, 35, 39, 43, 72, 73 and 76 year old humans (E & F). Intensity of PDX-
1 immunostaining relative to background in β-cells identified by doublestaining for insulin
in rat (D) and human (F) sections. In (D) results are shown as mean from five rats ± SE and
in (F) as a correlation between PDX-1 and age from 18 human pancreas sections. Ten islets
were scored in each section. + p < 0.05 relative to islets at 2 months of age. (G) Correlation
between age and RT-PCR quantification of PDX-1 mRNA expression in total RNA isolated
from 23 human islet isolations. The level of PDX-1 expression was normalized against
tubulin. Each datum point represents an independent experiment of one organ donor. Solid
lines are best fit, with broken lines showing 95% Cis.
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4.4 Discussion
Aging is a major risk factor for the development of type 2 diabetes. In cultivated
human islets, aging was negatively correlated with baseline β-cell proliferative ac-
tivity, and positively correlated with enhanced sensitivity to glucose-induced apop-
tosis. These in vitro observations are supported by Butler et al who show a trend
for decreased β-cell replication with age [6]. Thus, the limited adaptive capacity of
aging β-cells may contribute to the risk observed in elderly patients to develop type
2 diabetes.
Many differences exist between rat and human islets which are usually attributed
to differences in the genetic background. Indeed, islets from 2–3 month old rats
and human islets responded differently to glucose-induced changes in cell turnover.
However, while 2–3 month old rats are often considered to be adult, this is certainly
not the case in many aspects, including linear growth. No striking cell cycle differ-
ences were apparent when comparing human islets and islets from rats older than 6
months. This can be explained partly by the appearance of the Fas/FasL system. In-
deed, FasL is constitutively expressed by β-cells from rats aged 6 months and older
but not in younger rats, as previously shown [22] and confirmed in the present study.
Similarly, glucose induced Fas expression only in β-cells from 7–8 month old rats
and not at 2–3 months. Therefore, some differences between human islets, usually
emanating from adult organ donors, and rodent islets may be due to differences in
age and not in genetic background. However, we cannot rule out an intrinsic genetic
difference in the proliferative capacity between the species.
In human islets, baseline β-cell proliferation decreased with age. Furthermore,
prolonged exposure to 33.3 mM glucose decreased β-cell proliferation of cultured
islets from 7–8 month old rats and from adult humans. In parallel, both aging and
prolonged exposure to glucose were associated with decreased expression of PDX-
1. Interestingly, islets from 2–3 month old rats displayed a reduced expression of
PDX-1 only following a 96 h-exposure to high glucose but not after 30 h. Therefore,
changes in PDX-1 activity might contribute to these changes in proliferation rates.
Supporting this notion, PDX-1 has been shown to be important for β-cell replicative
activity and survival [24–26]. Furthermore, chronic exposure of cultured human
pancreatic islets to high glucose lowers the activity of PDX-1 [27]. Yet, our data are
correlative and a causative proof remains to be shown.
The observed changes in β-cell turnover most probably did not result in significant
changes in β-cell area in vitro. Indeed, a 4-day exposure of islets to elevated glucose
concentrations induced changes in apoptosis and proliferation in only 1–2% of the β-
cells. However, these findings may be relevant for the in vivo situation. Indeed, a net
increase of 1% in cell turnover will lead to a doubling in β-cell mass whereas a net
decrease of 1% will lead to a 50% decrease in β-cell mass, within 3–4 months. Such
impressive changes in β-cell mass may occur in vivo over a similar time period (e.g.
during obesity, see [6]). Nevertheless, in parallel to changes in β-cell turnover, aging
is associated with a progressive decrease in β-cell function, as previously described
[2, 30] and confirmed in the present study.
In conclusion, we demonstrate that there is a progressive impairment in β-cell
turnover with age, characterised by decreased baseline proliferation and enhanced
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sensitivity to glucose-induced β-cell apoptosis. This impairment is associated with
decreased PDX-1 expression. Furthermore, in rat islets, appearance with age of the
Fas/FasL pathway parallels changes in sensitivity to glucose-induced apoptosis and
decreased proliferation. Therefore, changes in β-cell plasticity may be a predispos-
ing factor to the development of diabetes in elderly subjects. Finally, islets of older
rats may be a more appropriate model than younger islets to study glucose-induced
β-cell apoptosis.
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5 Fas deficient mice are
protected from High-Fat diet
induced β-cell function
impairment.
Abstract
We have previously shown that the Fas receptor is needed for normal insulin se-
cretion. Here, we examined the role of Fas during the development of diabetes.
Wildtype and Fas deficient mice were fed a high fat diet for 4 weeks, after
which, the wildtype mice developed impaired glucose tolerance and insulin re-
sistance. Surprisingly, the Fas deficient mice, which exhibited impaired glucose
tolerance when fed normal chow, showed an improved glucose tolerance when
fed a high fat diet and no insulin resistance. Islets isolated from these animals,
showed that the Fas deficient mice on the high fat diet, had a significantly im-
proved glucose-stimulated insulin secretion, and an increase in insulin, Pdx-1,
c-myc and Pax4 mRNA levels, compared to Fas deficient mice on the normal
chow. Wildtype mice on a high fat diet had a decrease in all these genes. UCP-
2 was increased in the wildtype mice but not in the Fas deficient mice on the
high fat diet. This was confirmed in wildtype and Fas deficient islets exposed to
palmitic/oleic acid. Similarly, human islets cultured in the presence of an antag-
onistic anti-Fas antibody displayed impaired glucose-induced insulin secretion
which was reversed when treated with fatty acids. The glucotoxic effects of
glucose on wildtype islets were reversed on transfection with FLICE inhibitory
protein (FLIP). FLIP was able to improve glucose-induced insulin secretion,
by increasing insulin and PDX-1 mRNA levels. Therefore, modulation of the
Fas/FLIP pathway may prevent the development of type 2 diabetes.
5.1 Introduction
In humans, most obese individuals are able to adapt to their obesity and the resultant
insulin resistance by increasing β-cell mass and insulin secretion. In those individu-
als that are unable to adapt, the β-cell secretes less insulin and glucose homeostasis
is disrupted, resulting in hyperglycaemia and eventually type 2 diabetes. Impaired
beta cell function and loss of beta cell mass are therefore central to the development
of type 2 diabetes [1]. Hyperglycaemic conditions induce Fas in human islets which
results in increased β-cell apoptosis and decreased β-cell function [2–4]. The Fas
receptor, which is a member of the TNF superfamily, has long been recognized as
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a death receptor, but recent evidence has shown that the Fas receptor is directly in-
volved in proliferation [5, 6] and insulin secretion via the FLICE inhibitory protein
(FLIP, as detailed in Chapter 2). FLIP is an anti-apoptotic protein that blocks the
activation of procaspase-8 to caspase-8. In this study we sought to determine the
importance of the Fas/FLIP pathway in the development of type 2 diabetes by plac-
ing Fas deficient mice on a high energy diet for 4 weeks. We then looked at β-cell
function both in vivo and in vitro. The experiments were repeated in human islets
and the Fas receptor was blocked with an antagonistic anti-Fas antibody, ZB4.
5.2 Methods
5.2.1 Animal maintenance
Ethical approval for mouse studies was granted by the Zu¨rich Cantonal Animal Ex-
perimentation Committee. C57BL/6j (wildtype) and mice with a natural Fas muta-
tion backcrossed for more than 10 generations onto this same C57BL/6j inbred strain
background (B6.MRL-Tnfrsf6lpr, Fas deficient) were obtained from The Jackson
Laboratory (Bar Harbor, ME). Animals were housed at 22◦C with a 12-h light-dark
cycle (lights on at 07:00) and allowed free access to water and food. The wildtype
and Fas deficient mice were divided into 4 groups. Two groups were placed on a
normal Purina chow diet (Provimi Kliba AG, Kaiseraugst) and the other two groups
were placed on a high energy diet (HFD, Research Diets, New Brunswick, NJ). The
normal chow contained 29% fat compared to the HFD which contained 58% fat.
5.2.2 Islet isolation and culture
Pancreatic islets were isolated from wildtype and Fas deficient mice using Collage-
nase and an adapted protocol from Gotoh et al. [7]. After isolation, islets were cul-
tured on extracellular matrix-coated plates derived from bovine corneal endothelial
cells (Novamed Ltd., Jerusalem, Israel), and allowed to form a monolayer [8]. Islets
were cultured in RPMI 1640 medium (hereafter referred to as culture medium) con-
taining 100 U/ml penicillin, 100 µg/ml streptomycin, Fungizone, Gentamycin and
10% FCS (Invitrogen Ltd., Carlsbad, California). One day after plating the islets,
the medium was changed to culture medium containing 11.1 or 33.3 mM glucose. In
some experiments, the islets were transfected with either a RIP-only vector or with
a Rip-vector containing human FLIP cDNA.
5.2.3 Liposome-mediated transfection of mouse islets
Lipofectamine 2000-DNA complexes were prepared according to the manufacturer’s
instructions (Invitrogen Ltd., Carlsbad, California) using a RIP-FLAG-tagged FLIP
long construct or a RIP-only vector. The RIP-FLAG-tagged FLIP long vector was
constructed by excising FLAG-tagged FLIP from pCR3 using SmaI and XbaI. The
FLAG-tagged FLIP was inserted into a vector containing 640 bp rat insulin pro-
motor (RIP, kindly provided by T. Trueb, Zuerich, Switzerland). The solution was
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added to the islets at a final concentration of 3 µg of DNA/ml in Optimem. After 6
hours incubation, 2 ml culture medium was added, and after 24 hours, the medium
was aspirated and replaced with fresh culture medium according to the experimental
conditions needed.
5.2.4 Histochemical analysis
Beta-cell proliferation was detected with Ki-67 an affinity- purified goat polyclonal
antibody raised against mouse (Santa Cruz Biotechnology). Ki-67 is a nuclear anti-
gen expressed by proliferating cells and is used as a marker for late G1, S, G2, and
M phases of the cell cycle [9]. After washing with phosphate-buffered saline (PBS),
the islets were fixed in 4% paraformaldehyde for 30 minutes at room temperature,
followed by permeabilization with 0.5% Triton X-100 for 4 minutes at room tem-
perature. The cells were then incubated for 1 hour at room temperature with the
primary antibody diluted 1:50, followed by a PBS wash and then incubation with
the secondary antibody, donkey-anti-goat (Santa Cruz Biotechnology). To visualise
the beta-cells, we double-stained for insulin by incubating the islets for 30 minutes
at 37◦C with guinea pig anti-insulin antibody diluted 1:50 (Dako, Carpinteria, Cal-
ifornia), followed by a 30 minute incubation with a fluorescein-conjugated rabbit
anti-guinea pig antibody (1:15, Dako, Carpinteria, California). Free 3-OH strand
breaks, which are a result of DNA degradation, were detected by the terminal de-
oxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) technique.
The TUNEL assay thus allows one to quantify apoptosis. Whole pancreas tissue was
also sectioned to determine islet morphology. Islets were double-stained with insulin
and glucagon and thereafter surface area was measured using the analySISTM 3.1
software (Soft Imaging System GmbH, Muenster, Germany) program to determine
islet size.
5.2.5 RNA extraction and Quantitative Reverse
Transcription-PCR (RT-PCR)
Total RNA was extracted from the cultured islets by using the Rneasy mini kit (Qi-
agen, Basel, Switzerland) and reverse transcription was performed using the Super-
Script Double-Stranded cDNA synthesis kit according to the manufacturer’s instruc-
tions (Life Technologies, Invitrogen). For quantitative analysis, we used the Light
Cycler quantitative PCR system (Roche, Basel, Switzerland) and performed quanti-
tative PCR with a commercial kit, Light Cycler-DNA Master SYBR Green I (Roche,
Basel, Switzerland). We measured insulin, PDX-1, c-myc, Pax4, UCP-2 and human
FLIP mRNA using the following primers: insulin – 5′ TACGGGGTTTGTGAAAG-
GAG 3′ and 5′ CACATCATTCCCCAGGAAAC 3′; PDX-1 – 5′ GAGGACCCG-
TACAGCCTACA 3′ and 5′ CGTTGTCCCGCTACTACGTT 3′; c-myc – 5′ TCTC-
CACTCACCAGCACAAC 3′ and 5′ AATTCAGGGATCTGGTCACG 3′; Pax4 –
5′ GCTCTTTTTGCCTGGGAGATC 3′ and 5′ CCCGAAGGACTCGATTGATAGA
3′ UCP-2 – 5′ CAGCCAGCGCCCAGTACC 3′ and 5′ CAATGCGGACGGAGGC-
AAAGC 3′ and human FLIP – 5′ CTAAATTTGGTTGCCCCAGA 3′ and 5′ CTCC-
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CATTATGGAGCCTGAA 3′.
5.2.6 Insulin secretion and content
To determine acute glucose stimulated insulin release, cultured islets were preincu-
bated in Krebs Ringer Buffer containing 3.3 mM glucose for 30 minutes in at 37◦C
in air. This medium was aspirated and the islets re-incubated in Krebs Ringer buffer
containing 3.3 mM glucose for 1 hour at 37◦C in air. This was to determine basal
insulin secretion. Thereafter, the islets were incubated in Krebs Ringer buffer con-
taining 16.7 mM glucose for 1 hour at 37◦C in air. For insulin content, the islets were
exposed to 0.18 N HCl in 70% ethanol for 24 hours at 4◦C. Insulin was measured
using a human insulin RIA kit (CIS Biointernational, Gif-Sur-Yvette, France) which
was tested and shown to cross-react with mouse insulin.
5.2.7 Intra-peritoneal glucose tolerance test (IPGTT) and
intra-peritoneal insulin tolerance test (IPITT)
An IPGTT was performed to characterize the glucose tolerance of Fas-deficient mice
compared to wildtype mice. The mice were maintained on a either a normal chow or
high fat diet (HFD) and water ad libitum before being fasted overnight (12 hours),
and then injected intraperitoneally with 40% glucose solution (2 mg/g body weight,
Glucosum, Dr. G. Bichsel). Glucose was administered with a 0.5 ml (U-100) in-
sulin syringe (Becton Dickinson AG, Basel, Switzerland) through a 29 gauge nee-
dle. Blood glucose concentration was measured before (0 min) and 15, 30, 60, and
90 minutes after glucose injection with a Freestyle glucometer (Disetronic Medical
Systems, Burgdorf, Switzerland). An intraperitoneal insulin tolerance test was per-
formed on overnight fasted animals (12 hours). Blood glucose was measured at time
0 before insulin injection and 15, 30 and 60 minutes after insulin injection (0.75 U/kg
Actrapid, Novo Nordisk, Copenhagen, Denmark).
5.2.8 In situ pancreas perfusion
Wildtype and Fas deficient mice aged 7-8 weeks, were anaesthetised with sodium
pentothal 100 mg/kg bodyweight intraperitoneally and prepared for pancreas perfu-
sion as previously described [10]. The pancreas was perfused at 37◦C with modified
Krebs Ringer HEPES buffer supplemented with the indicated glucose concentra-
tions. The perfusion was maintained at 1 ml/min through the aorta into the pan-
creas. The pancreatic effluent of the first 30 minutes of perfusion with basal glucose
(2.8 mM) was discarded. After this equilibration period, the effluent was collected
in 1 min fractions from a catheter placed in the portal vein. The insulin content of
each fraction was determined by radioimmunoassay.
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5.3 Results
High fat diet improves insulin secretion without development of
insulin resistance in Fas deficient mice
Wildtype and Fas deficient mice on HFD gained a significant amount of weight dur-
ing the treatment compared to the wildtype and Fas deficient mice on normal chow
(Fig. 5.1 a). There were no differences in fasting blood glucose concentrations for
wildtype and Fas deficient mice on the normal chow diet (Fig. 5.1 b). HFD wildtype
mice significantly increased their fasting blood glucose compared with normal chow
wildtype mice, but this increase did not occur in the Fas deficient mice (Fig. 5.1 b).
After a high fat diet, wildtype mice showed impaired glucose tolerance compared
to wildtype mice on normal chow. Interestingly, Fas deficient mice on high fat diet
had significantly improved glucose tolerance compared to Fas deficient mice on the
normal chow diet. Insulin tolerance test showed no difference between wildtype and
Fas deficient mice on normal chow (Fig. 5.1 d). Surprisingly, unlike the wildtype
mice on high fat diet, the Fas deficient mice on a high fat diet showed no insulin
resistance. This was confirmed with a glucose uptake test on adipocytes (Fig. 5.1 e).
In situ pancreatic perfusions showed a 2-minute delay in glucose stimulated in-
sulin secretion by Fas-deficient mice on normal chow as well as a blunted glucose
stimulated insulin secretion compared to wildtype mice on normal chow (Fig. 5.1 f).
After a high fat diet, the Fas deficient mice showed normal glucose stimulated insulin
secretion, with clear first and second phase insulin secretion (Fig. 5.1 f).
To determine the effects of the high fat diet on β-cell morphology and mass, we
looked at pancreatic sections from Fas deficient and wildtype mice. The distribution
of β- and α-cells was normal in the Fas-deficient islets compared to the wildtype
islets for both diets. Islets from wildtype mice on high fat diet showed a not sig-
nificant increase in size, compared to normal chow wildtype mice whereas islets
from Fas deficient mice on high fat diet showed a not significant decrease in size,
compared to normal chow Fas deficient mice (Fig. 5.1 g).
Since there were no significant changes in β-cell mass, we decided to have a closer
look at the islets. Islets from wildtype mice on the high fat diet had a significant de-
crease in glucose-induced insulin secretion compared to islets from wildtype mice
on normal chow (Fig. 5.1 h). As previously shown in Chapter 2, Fas deficient mice
on normal chow have a significant decrease in glucose stimulated insulin secretion
compared to wildtype mice on normal chow. After the high fat diet, islets from Fas
deficient mice showed a significant improvement in glucose-induced insulin secre-
tion (Fig. 5.1 h). Gene expression analysis yielded a significant increase in insulin,
PDX-1, c-myc and Pax4 mRNA in islets from Fas deficient mice on a high fat diet,
compared to Fas deficient mice on a normal chow diet, whereas there is a significant
decrease in these genes in islets from wildtype mice on a high fat diet (Fig. 5.1 i).
UCP2 was significantly increased in the islets from wildtype mice on a high fat diet
compared to islets from wildtype mice on a normal chow diet, but stayed unchanged
in the Fas deficient islets (Fig. 5.1 i).
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Figure 5.1: High fat diet improves insulin secretion in Fas deficient mice without develop-
ment of insulin resistance. (a) Body weight of Fas deficient and wildtype mice placed on a
high fat diet and on normal chow for 4 weeks and weighed weekly. (b) Fasting blood glucose
levels after 12 hours of fasting. (c) Blood glucose levels following i.p. injection of glucose
(2 mg/g body weight) in wildtype mice on normal chow (NC) vs. wildtype on a high fat diet
(HFD), upper panel, and Fas deficient on normal chow (NC) vs. Fas deficient on a high fat
diet (HFD), lower panel. * indicates p < 0.05, wildtype NC vs. wildtype HFD; # denotes
p < 0.05, Fas deficient NC vs. Fas deficient HFD; n = 10 for each group. (d) Blood glucose
levels following i.p. injection of insulin (0.75 mU/kg) in male Fas deficient versus wildtype
mice on normal chow (NC) and high fat diet (HFD); n = 10 for each group. (e) Insulin-
stimulated 2-Deoxyglucose uptake in adipocytes isolated from Fas deficient and wildtype
mice on normal chow and high fat diet. Data are the means of 2 separate experiments, each
in sextuplet.* indicates p < 0.05 vs. wildtype normal chow. (f) Glucose induced insulin
secretion in perfused pancreata from Fas deficient and wildtype mice. Pancreata were per-
fused with basal solution (2.8 mM glucose) for 30 min before perfusate was collected (from
time 0). Glucose was increased to 16.7 mM glucose for the indicated period, n = 3 for
each group. (g) Pancreatic sections of Fas deficient and wildtype mice on a high fat diet
or a normal chow diet were stained for insulin and glucagon. The area of the islets were
measured using analySISTM computer software. (h) Stimulatory index of insulin secretion
during successive 1 h incubation at 3.3 mM glucose (basal) and 16.7 mM glucose (stim-
ulated) following a 4 day culture period of islets isolated from Fas deficient and wildtype
mice on normal chow and high fat diet. Data are the means of 3 separate experiments, each
in triplicate. * indicates p < 0.05 vs. wildtype normal chow, ** indicates p < 0.05 vs. Fas
deficient normal chow. (i) Quantitative RT-PCR detection of insulin, PDX-1, c-myc, Pax4
and uncoupling protein 2 (UCP-2) mRNA expression. Total RNA was isolated from Fas
deficient and wildtype islets of mice on normal chow and high fat diet. The level of mRNA
expression was normalized to GAPDH and the results expressed as percentage of wildtype
normal chow islet mRNA levels; n = 3 for each group. * denotes p < 0.05.
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Figure 5.2: Fatty acids improve insulin secretion and chronic hyperglycaemia does not im-
pair β-cell function in Fas deficient islets. (a) Stimulatory index of insulin secretion during
successive 1 h incubation at 3.3 mM glucose (basal) and 16.7 mM glucose (stimulated) fol-
lowing a 2 day culture period of islets isolated from Fas deficient and wildtype mice (left
panel) and human cadaveric donors (right panel)with palmitic/oleic acid. The human islets
were exposed to 500 ng/ml isotype IgG (control) or 500 ng/ml antagonistic anti-Fas antibody
(ZB4). (b) After a 4 day culture period, wildtype and Fas deficient mouse islets (left panel)
and human islets cultured in the presence of 500 ng/ml isotype IgG (control) or 500 ng/ml
antagonistic anti-Fas antibody (ZB4) (right panel), were incubated successively for 30 min
in 2.8 mM glucose followed by an additional 10 min in 16.7 mM glucose and analysed for
stimulated ATP-content. * indicates p < 0.001. Data are means of percentage relative to
control for 3 separate experiments, each in triplicate. (c) Stimulatory index of insulin secre-
tion during successive 1 h incubation at 3.3 mM glucose and 16.7 mM glucose following
an 8 day culture period of islets isolated from wildtype and Fas deficient mice. Islets were
chronically treated with 33.3 mM glucose only or transfected with a vector encoding for
FLIP and then exposed to 33.3 mM glucose. (d–e) Quantitative RT-PCR detection of insulin
and PDX-1 mRNA expression. The level of mRNA expression was normalized to tubulin
and the results expressed as mRNA levels relative to controls. n = 3 to 4 independent exper-
iments. * denotes p < 0.05 relative to wildtype controls and # p < 0.05 relative to wildtype
33.3 mM glucose.
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Fatty acids improve the function of Fas deficient β-cells which are
protected from lipotoxicity
Free fatty acids (FFA) decreased the glucose-induced stimulatory index in wildtype
islets, but improved the glucose-induced stimulatory index in Fas deficient islets
(Fig. 5.2 a). This confirmed the in vivo results. Human islets treated with FFA
showed an impairment in function, but treatment with the antagonistic anti-Fas anti-
body, ZB4, and FFA abrogated these effects (Fig. 5.2 a, right panel). As a possible
mechanism, we looked at mitochondrial function, and in both human and mouse
islets, there was a decrease in ATP content in wildtype/control islets treated with
FFA, whereas there was a not significant increase in ATP content in the Fas defi-
cient/ZB4 treated islets with FFA (Fig. 5.2 b).
FLIP reverses glucotoxic effects on wildtype islets
There was a significant decrease in insulin secretion in wildtype islets exposed to
33.3 mM glucose whereas there was no significant decrease in insulin secretion in the
Fas deficient islets (Fig. 5.2 c). The decrease in glucose stimulated insulin secretion
in wildtype mice, could be improved when the islets were transfected with FLICE
inhibitory protein (FLIP), which is found downstream of Fas. With gene expression
analysis, we saw that the decrease in β-cell function in wildtype islets exposed to
high glucose was due to a significant decrease in insulin and PDX-1 mRNA. FLIP
increased both insulin and PDX-1 mRNA and improved the function. There were
no glucose-induced changes in insulin or PDX-1 mRNA in the Fas deficient islets
(Fig. 5.2 d and Fig. 5.2 e).
5.4 Discussion
Diet-induced obesity is a well-known mechanism for inducing diabetes in mice [11].
In our mouse model, we were able to induce increased fasting glucose, impaired
glucose tolerance and insulin resistance after four weeks on a high fat diet, with no
significant changes in β-cell mass. Fas deficient mice on the high fat diet, had an
increase in weight similar to the wildtype mice on a high fat diet, but did not develop
insulin resistance, or impaired fasting glucose and surprisingly had an improved glu-
cose tolerance. The increase in glucose-induced insulin secretion in the Fas deficient
mice after a high fat diet compared to the Fas deficient mice on a normal chow diet,
could be due to the fact that no insulin resistance developed. Insulin resistance oc-
curs when insulin is unable to induce the uptake of glucose by peripheral tissues
such as muscle and fat. This results in increased circulating glucose, which in turn
induces apoptosis and impairs β-cell function via IL-1βand Fas [2]. The glucotoxic
effects which occurred in the wildtype mice on a high fat diet included decreased
insulin and PDX-1 mRNA as well as decreased glucose-induced insulin secretion,
therefore, did not occur in the Fas deficient mice on a high fat diet. On the contrary,
the Fas deficient mice on the high fat diet had increased insulin and PDX-1 mRNA.
Transfection of wildtype isolates with FLIP, which is found downstream of Fas, re-
versed the glucotoxic effects by increasing both insulin and PDX-1 mRNA. Since the
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improvement in β-cell function in the Fas deficient mouse islets as well as in human
islets treated with an antagonistic anti-Fas antibody, ZB4, was also evident in the in
vitro studies, more factors appear to play a role. The production of mitochondrial
ATP is critical for glucose-stimulated insulin secretion, therefore we investigated
uncoupling protein 2 (UCP-2), the only uncoupling protein present in islets and a
known regulator of mitochondrial ATP production [12, 13]. In the wildtype mice
on a high fat diet, UCP-2 was significantly increased and ATP was significantly de-
creased after the high fat diet, whereas in Fas deficient mice on a high fat diet UCP-2
and ATP remained unchanged. The increased UCP-2 in the wildtype mice possibly
increased proton leak and decreased the mitochondrial ATP production, which in
turn decreased glucose-stimulated insulin secretion. When exposed to high glucose
for a prolonged time period, Fas deficient islets proved to be impervious to gluco-
toxicity, since there were no changes in β-cell function or in the insulin and PDX-1
mRNA. It therefore appears that regulation of the Fas/FLIP pathway could be a tool
used in the fight against type 2 diabetes.
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